BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9:454-467. [PMID: 22710569 DOI: 10.1038/nrgastro.2012.115] [Cited by in Crossref: 353] [Cited by in F6Publishing: 340] [Article Influence: 39.2] [Reference Citation Analysis]
Number Citing Articles
1 Berchtold S, Grünwald B, Krüger A, Reithmeier A, Hähl T, Cheng T, Feuchtinger A, Born D, Erkan M, Kleeff J, Esposito I. Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Cancer Lett 2015;356:721-32. [PMID: 25449434 DOI: 10.1016/j.canlet.2014.10.020] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
2 Mehta A, Hwang WL, Weekes C. The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma. Ann Pancreat Cancer 2020;3:3. [PMID: 33294843 DOI: 10.21037/apc-2020-pda-05] [Reference Citation Analysis]
3 Zhang L, Chen Z, Yang K, Liu C, Gao J, Qian F. β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy. Mol Pharm 2015;12:3999-4010. [PMID: 26415823 DOI: 10.1021/acs.molpharmaceut.5b00448] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
4 Drifka CR, Loeffler AG, Mathewson K, Mehta G, Keikhosravi A, Liu Y, Lemancik S, Ricke WA, Weber SM, Kao WJ, Eliceiri KW. Comparison of Picrosirius Red Staining With Second Harmonic Generation Imaging for the Quantification of Clinically Relevant Collagen Fiber Features in Histopathology Samples. J Histochem Cytochem 2016;64:519-29. [PMID: 27449741 DOI: 10.1369/0022155416659249] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 8.6] [Reference Citation Analysis]
5 Long J, Lin J, Wang A, Wu L, Zheng Y, Yang X, Wan X, Xu H, Chen S, Zhao H. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. J Hematol Oncol. 2017;10:146. [PMID: 28774337 DOI: 10.1186/s13045-017-0511-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
6 El-Zahaby SA, Elnaggar YSR, Abdallah OY. Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: An emphasis on state of art. J Control Release 2019;293:21-35. [PMID: 30445002 DOI: 10.1016/j.jconrel.2018.11.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
7 Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther 2021;221:107753. [PMID: 33259885 DOI: 10.1016/j.pharmthera.2020.107753] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
8 Mao M, Ling H, Lin Y, Chen Y, Xu B, Zheng R. Construction and Validation of an Immune-Based Prognostic Model for Pancreatic Adenocarcinoma Based on Public Databases. Front Genet 2021;12:702102. [PMID: 34335699 DOI: 10.3389/fgene.2021.702102] [Reference Citation Analysis]
9 Zuo ZQ, Chen KG, Yu XY, Zhao G, Shen S, Cao ZT, Luo YL, Wang YC, Wang J. Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-β signaling pathway inhibition. Biomaterials 2016;82:48-59. [PMID: 26751819 DOI: 10.1016/j.biomaterials.2015.12.014] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 11.0] [Reference Citation Analysis]
10 Peng YP, Xi CH, Zhu Y, Yin LD, Wei JS, Zhang JJ, Liu XC, Guo S, Fu Y, Miao Y. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer. Oncotarget. 2016;7:66586-66594. [PMID: 27626490 DOI: 10.18632/oncotarget.11953] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
11 Trujillo-de Santiago G, Flores-Garza BG, Tavares-Negrete JA, Lara-Mayorga IM, González-Gamboa I, Zhang YS, Rojas-Martínez A, Ortiz-López R, Álvarez MM. The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors. Materials (Basel) 2019;12:E2945. [PMID: 31514390 DOI: 10.3390/ma12182945] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 23.0] [Reference Citation Analysis]
12 Kokkinos J, Sharbeen G, Haghighi KS, Ignacio RMC, Kopecky C, Gonzales-Aloy E, Youkhana J, Timpson P, Pereira BA, Ritchie S, Pandzic E, Boyer C, Davis TP, Butler LM, Goldstein D, McCarroll JA, Phillips PA. Ex vivo culture of intact human patient derived pancreatic tumour tissue. Sci Rep 2021;11:1944. [PMID: 33479301 DOI: 10.1038/s41598-021-81299-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
13 Han B, Qu C, Park K, Konieczny SF, Korc M. Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip. Cancer Lett 2016;380:319-29. [PMID: 26688098 DOI: 10.1016/j.canlet.2015.12.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
14 Liu D, Steins A, Klaassen R, van der Zalm AP, Bennink RJ, van Tienhoven G, Besselink MG, Bijlsma MF, van Laarhoven HWM. Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma. Biomedicines 2020;8:E444. [PMID: 33105540 DOI: 10.3390/biomedicines8110444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lu T, Prakash J. Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer. Int J Nanomedicine 2021;16:6313-28. [PMID: 34552327 DOI: 10.2147/IJN.S279192] [Reference Citation Analysis]
16 Chen J, Diamond DJ, Manuel ER. Developing Effective Salmonella-based Approaches to Treat Pancreatic Cancer. Pancreat Disord Ther 2016;6:1-2. [PMID: 26925306 DOI: 10.4172/2165-7092.1000167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Spano C, Grisendi G, Golinelli G, Rossignoli F, Prapa M, Bestagno M, Candini O, Petrachi T, Recchia A, Miselli F, Rovesti G, Orsi G, Maiorana A, Manni P, Veronesi E, Piccinno MS, Murgia A, Pinelli M, Horwitz EM, Cascinu S, Conte P, Dominici M. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Sci Rep 2019;9:1788. [PMID: 30742129 DOI: 10.1038/s41598-018-37433-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 11.5] [Reference Citation Analysis]
18 Phan VT, Wu X, Cheng JH, Sheng RX, Chung AS, Zhuang G, Tran C, Song Q, Kowanetz M, Sambrone A. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci USA. 2013;110:6079-6084. [PMID: 23530240 DOI: 10.1073/pnas.1303302110] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 9.1] [Reference Citation Analysis]
19 Park K, Bae YH, Mrsny RJ. The Missing Components Today and the New Treatments Tomorrow. In: Bae YH, Mrsny RJ, Park K, editors. Cancer Targeted Drug Delivery. New York: Springer; 2013. pp. 689-707. [DOI: 10.1007/978-1-4614-7876-8_26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
20 Hossen MN, Rao G, Dey A, Robertson JD, Bhattacharya R, Mukherjee P. Gold Nanoparticle Transforms Activated Cancer-Associated Fibroblasts to Quiescence. ACS Appl Mater Interfaces 2019;11:26060-8. [PMID: 31117437 DOI: 10.1021/acsami.9b03313] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
21 Baues M, Dasgupta A, Ehling J, Prakash J, Boor P, Tacke F, Kiessling F, Lammers T. Fibrosis imaging: Current concepts and future directions. Adv Drug Deliv Rev 2017;121:9-26. [PMID: 29108860 DOI: 10.1016/j.addr.2017.10.013] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 15.8] [Reference Citation Analysis]
22 Ji T, Lang J, Wang J, Cai R, Zhang Y, Qi F, Zhang L, Zhao X, Wu W, Hao J, Qin Z, Zhao Y, Nie G. Designing Liposomes To Suppress Extracellular Matrix Expression To Enhance Drug Penetration and Pancreatic Tumor Therapy. ACS Nano 2017;11:8668-78. [PMID: 28806504 DOI: 10.1021/acsnano.7b01026] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 24.3] [Reference Citation Analysis]
23 Perales S, Torres C, Jimenez-Luna C, Prados J, Martinez-Galan J, Sanchez-Manas JM, Caba O. Liquid biopsy approach to pancreatic cancer. World J Gastrointest Oncol 2021; 13(10): 1263-1287 [PMID: 34721766 DOI: 10.4251/wjgo.v13.i10.1263] [Reference Citation Analysis]
24 Liu Y, Tang T, Yang X, Qin P, Wang P, Zhang H, Bai M, Wu R, Li F. Tumor-derived exosomal long noncoding RNA LINC01133, regulated by Periostin, contributes to pancreatic ductal adenocarcinoma epithelial-mesenchymal transition through the Wnt/β-catenin pathway by silencing AXIN2. Oncogene 2021;40:3164-79. [PMID: 33824474 DOI: 10.1038/s41388-021-01762-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Gao F, Wu J, Niu S, Sun T, Li F, Bai Y, Jin L, Lin L, Shi Q, Zhu LM, Du L. Biodegradable, pH-Sensitive Hollow Mesoporous Organosilica Nanoparticle (HMON) with Controlled Release of Pirfenidone and Ultrasound-Target-Microbubble-Destruction (UTMD) for Pancreatic Cancer Treatment. Theranostics 2019;9:6002-18. [PMID: 31534533 DOI: 10.7150/thno.36135] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
26 Thillai K, Lam H, Sarker D, Wells CM. Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer? Oncotarget 2017;8:14173-91. [PMID: 27845911 DOI: 10.18632/oncotarget.13309] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
27 Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol 2020; 12(2): 173-181 [PMID: 32104548 DOI: 10.4251/wjgo.v12.i2.173] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 31.0] [Reference Citation Analysis]
28 Tanaka HY, Kitahara K, Sasaki N, Nakao N, Sato K, Narita H, Shimoda H, Matsusaki M, Nishihara H, Masamune A, Kano MR. Pancreatic stellate cells derived from human pancreatic cancer demonstrate aberrant SPARC-dependent ECM remodeling in 3D engineered fibrotic tissue of clinically relevant thickness. Biomaterials 2019;192:355-67. [DOI: 10.1016/j.biomaterials.2018.11.023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
29 Miksch RC, Schoenberg MB, Weniger M, Bösch F, Ormanns S, Mayer B, Werner J, Bazhin AV, D'Haese JG. Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer. Cancers (Basel) 2019;11:E39. [PMID: 30609853 DOI: 10.3390/cancers11010039] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 20.0] [Reference Citation Analysis]
30 Federau C. Intravoxel incoherent motion MRI as a means to measure in vivo perfusion: A review of the evidence. NMR Biomed. 2017;30. [PMID: 28885745 DOI: 10.1002/nbm.3780] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
31 Stangel D, Erkan M, Buchholz M, Gress T, Michalski C, Raulefs S, Friess H, Kleeff J. Kif20a inhibition reduces migration and invasion of pancreatic cancer cells. J Surg Res 2015;197:91-100. [PMID: 25953216 DOI: 10.1016/j.jss.2015.03.070] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 5.5] [Reference Citation Analysis]
32 Aroldi F, Zaniboni A. Immunotherapy for pancreatic cancer: Present and future. Immunotherapy. 2017;9:607-616. [PMID: 28595517 DOI: 10.2217/imt-2016-0142] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
33 Di Maggio F, El-Shakankery KH. Desmoplasia and Biophysics in Pancreatic Ductal Adenocarcinoma: Can We Learn From Breast Cancer? Pancreas. 2020;49:313-325. [PMID: 32168249 DOI: 10.1097/mpa.0000000000001504] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
34 Wang CY, Lin BL, Chen CH. Targeted drug delivery using an aptamer against shared tumor-specific peptide antigen of MAGE-A3. Cancer Biol Ther 2021;22:12-8. [PMID: 33249980 DOI: 10.1080/15384047.2020.1833156] [Reference Citation Analysis]
35 Hu X, Xia F, Lee J, Li F, Lu X, Zhuo X, Nie G, Ling D. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma. Adv Sci (Weinh) 2021;8:2002545. [PMID: 33854877 DOI: 10.1002/advs.202002545] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
36 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-337. [PMID: 23814611 DOI: 10.1177/1756283x13478680] [Cited by in Crossref: 155] [Cited by in F6Publishing: 102] [Article Influence: 19.4] [Reference Citation Analysis]
37 Liu ST, Pham H, Pandol SJ, Ptasznik A. Src as the link between inflammation and cancer. Front Physiol 2013;4:416. [PMID: 24474940 DOI: 10.3389/fphys.2013.00416] [Cited by in Crossref: 18] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
38 Martínez-Bosch N, Fernández-Barrena MG, Moreno M, Ortiz-Zapater E, Munné-Collado J, Iglesias M, André S, Gabius HJ, Hwang RF, Poirier F, Navas C, Guerra C, Fernández-Zapico ME, Navarro P. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Res 2014;74:3512-24. [PMID: 24812270 DOI: 10.1158/0008-5472.CAN-13-3013] [Cited by in Crossref: 75] [Cited by in F6Publishing: 47] [Article Influence: 10.7] [Reference Citation Analysis]
39 Wang Y, Wang D, Dai Y, Kong X, Zhu X, Fan Y, Wang Y, Wu H, Jin J, Yao W, Gao J, Wang K, Xu H. Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma. Front Oncol 2021;11:652283. [PMID: 34046348 DOI: 10.3389/fonc.2021.652283] [Reference Citation Analysis]
40 Foulkes R, Ali Asgari M, Curtis A, Hoskins C. Silver-Nanoparticle-Mediated Therapies in the Treatment of Pancreatic Cancer. ACS Appl Nano Mater 2019;2:1758-72. [DOI: 10.1021/acsanm.9b00439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
41 Hessmann E, Patzak MS, Klein L, Chen N, Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM. Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut. 2018;67:497-507. [PMID: 28077438 DOI: 10.1136/gutjnl-2016-311954] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 22.5] [Reference Citation Analysis]
42 Teicher BA. Perspective: Opportunities in recalcitrant, rare and neglected tumors. Oncol Rep 2013;30:1030-4. [PMID: 23820887 DOI: 10.3892/or.2013.2581] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
43 Zhu L, Fan X, Wang B, Liu L, Yan X, Zhou L, Zeng Y, Poznansky MC, Wang L, Chen H, Du Y. Biomechanically primed liver microtumor array as a high-throughput mechanopharmacological screening platform for stroma-reprogrammed combinatorial therapy. Biomaterials 2017;124:12-24. [PMID: 28182873 DOI: 10.1016/j.biomaterials.2017.01.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
44 Wei Y, Wang Y, Xia D, Guo S, Wang F, Zhang X, Gan Y. Thermosensitive Liposomal Codelivery of HSA–Paclitaxel and HSA–Ellagic Acid Complexes for Enhanced Drug Perfusion and Efficacy Against Pancreatic Cancer. ACS Appl Mater Interfaces 2017;9:25138-51. [DOI: 10.1021/acsami.7b07132] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
45 Wang LM, Silva MA, D'Costa Z, Bockelmann R, Soonawalla Z, Liu S, O'Neill E, Mukherjee S, McKenna WG, Muschel R, Fokas E. The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 2016;7:4183-94. [PMID: 26716653 DOI: 10.18632/oncotarget.6770] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 11.2] [Reference Citation Analysis]
46 Drifka CR, Loeffler AG, Esquibel CR, Weber SM, Eliceiri KW, Kao WJ. Human pancreatic stellate cells modulate 3D collagen alignment to promote the migration of pancreatic ductal adenocarcinoma cells. Biomed Microdevices 2016;18:105. [PMID: 27819128 DOI: 10.1007/s10544-016-0128-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
47 Nsingwane Z, Candy G, Devar J, Omoshoro-Jones J, Smith M, Nweke E. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects. Mol Biol Rep 2020;47:6269-80. [PMID: 32661873 DOI: 10.1007/s11033-020-05648-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Mei L, Du W, Ma WW. Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. J Gastrointest Oncol. 2016;7:487-494. [PMID: 27284483 DOI: 10.21037/jgo.2016.03.03] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
49 Lee JJ, Huang J, England CG, McNally LR, Frieboes HB. Predictive modeling of in vivo response to gemcitabine in pancreatic cancer. PLoS Comput Biol 2013;9:e1003231. [PMID: 24068909 DOI: 10.1371/journal.pcbi.1003231] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
50 Belhabib I, Zaghdoudi S, Lac C, Bousquet C, Jean C. Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy? Cancers (Basel) 2021;13:3466. [PMID: 34298680 DOI: 10.3390/cancers13143466] [Reference Citation Analysis]
51 Nishida T, Yoshitomi H, Takano S, Kagawa S, Shimizu H, Ohtsuka M, Kato A, Furukawa K, Miyazaki M. Low Stromal Area and High Stromal Microvessel Density Predict Poor Prognosis in Pancreatic Cancer. Pancreas 2016;45:593-600. [PMID: 26495781 DOI: 10.1097/MPA.0000000000000499] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
52 Liu Q, Li Y, Niu Z, Zong Y, Wang M, Yao L, Lu Z, Liao Q, Zhao Y. Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages. J Exp Clin Cancer Res. 2016;35:33. [PMID: 26879926 DOI: 10.1186/s13046-016-0304-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
53 Kahlert C, Fiala M, Musso G, Halama N, Keim S, Mazzone M, Lasitschka F, Pecqueux M, Klupp F, Schmidt T, Rahbari N, Schölch S, Pilarsky C, Ulrich A, Schneider M, Weitz J, Koch M. Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. Oncotarget 2014;5:12978-89. [PMID: 25483099 DOI: 10.18632/oncotarget.2651] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
54 Erkan M, Brocks T, Friess H. The Role of Non-cancerous Cells in Cancer: Pancreatic Ductal Adenocarcinoma as a Model to Understand the Impact of Tumor Microenvironment on Epithelial Carcinogenesis. In: Bae YH, Mrsny RJ, Park K, editors. Cancer Targeted Drug Delivery. New York: Springer; 2013. pp. 309-33. [DOI: 10.1007/978-1-4614-7876-8_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Delitto D, Zhang D, Han S, Black BS, Knowlton AE, Vlada AC, Sarosi GA, Behrns KE, Thomas RM, Lu X, Liu C, George TJ, Hughes SJ, Wallet SM, Trevino JG. Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment. Clin Cancer Res. 2016;22:1787-1799. [PMID: 26667487 DOI: 10.1158/1078-0432.ccr-15-1256] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
56 Delayre T, Guilbaud T, Resseguier N, Mamessier E, Rubis M, Moutardier V, Fara R, Berdah SV, Garcia S, Birnbaum DJ. Prognostic impact of tumour-infiltrating lymphocytes and cancer-associated fibroblasts in patients with pancreatic adenocarcinoma of the body and tail undergoing resection. Br J Surg 2020;107:720-33. [PMID: 31960955 DOI: 10.1002/bjs.11434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
57 Perkhofer L, Beutel AK, Ettrich TJ. Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer. Visc Med 2019;35:28-37. [PMID: 31312647 DOI: 10.1159/000497291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
58 Pereira PMR, Edwards KJ, Mandleywala K, Carter LM, Escorcia FE, Campesato LF, Cornejo M, Abma L, Mohsen AA, Iacobuzio-Donahue CA, Merghoub T, Lewis JS. iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. Cancer Res 2020;80:1681-92. [PMID: 32086240 DOI: 10.1158/0008-5472.CAN-19-2991] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
59 Görgülü K, Diakopoulos KN, Kaya-Aksoy E, Ciecielski KJ, Ai J, Lesina M, Algül H. The Role of Autophagy in Pancreatic Cancer: From Bench to the Dark Bedside. Cells 2020;9:E1063. [PMID: 32344698 DOI: 10.3390/cells9041063] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
60 Acier A, Godard M, Gassiot F, Finetti P, Rubis M, Nowak J, Bertucci F, Iovanna JL, Tomasini R, Lécorché P, Jacquot G, Khrestchatisky M, Temsamani J, Malicet C, Vasseur S, Guillaumond F. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma. Commun Biol 2021;4:987. [PMID: 34413441 DOI: 10.1038/s42003-021-02508-0] [Reference Citation Analysis]
61 Jin Y, Zhang Z, Zou S, Li F, Chen H, Peng C, Deng X, Wen C, Shen B, Zhan Q. A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer. Front Oncol 2021;11:634881. [PMID: 33816276 DOI: 10.3389/fonc.2021.634881] [Reference Citation Analysis]
62 Kramer RM, Russell J, Humm JL. Distribution of Gemcitabine Is Nearly Homogenous in Two Orthotopic Murine Models of Pancreatic Cancer. Cancer Biother Radiopharm 2015;30:299-304. [PMID: 26203552 DOI: 10.1089/cbr.2015.1869] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
63 Donahue TR, Dawson DW. Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality. Trends Endocrinol Metab 2016;27:770-81. [PMID: 27461042 DOI: 10.1016/j.tem.2016.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
64 Schneider G, Schmidt-Supprian M, Rad R, Saur D. Tissue-specific tumorigenesis: context matters. Nat Rev Cancer 2017;17:239-53. [PMID: 28256574 DOI: 10.1038/nrc.2017.5] [Cited by in Crossref: 149] [Cited by in F6Publishing: 132] [Article Influence: 37.3] [Reference Citation Analysis]
65 Inoue KI, Kishimoto S, Akimoto K, Sakuma M, Toyoda S, Inoue T, Yoshida KI, Shimoda M, Suzuki S. Cancer-associated fibroblasts show heterogeneous gene expression and induce vascular endothelial growth factor A (VEGFA) in response to environmental stimuli. Ann Gastroenterol Surg 2019;3:416-25. [PMID: 31346581 DOI: 10.1002/ags3.12249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Saha S, Xiong X, Chakraborty PK, Shameer K, Arvizo RR, Kudgus RA, Dwivedi SK, Hossen MN, Gillies EM, Robertson JD, Dudley JT, Urrutia RA, Postier RG, Bhattacharya R, Mukherjee P. Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth. ACS Nano 2016;10:10636-51. [PMID: 27758098 DOI: 10.1021/acsnano.6b02231] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 15.6] [Reference Citation Analysis]
67 Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA, Chen CS, Ludwig T, Bekaii-Saab T, Chakravarti A, Williams TM. Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. Sci Rep 2015;5:10867. [PMID: 26065715 DOI: 10.1038/srep10867] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 8.5] [Reference Citation Analysis]
68 Bradney MJ, Venis SM, Yang Y, Konieczny SF, Han B. A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma. Small 2020;16:e1905500. [PMID: 31997571 DOI: 10.1002/smll.201905500] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
69 Ahmad E, Ali A, Fatima MT, Nimisha, Apurva, Kumar A, Sumi MP, Sattar RSA, Mahajan B, Saluja SS. Ligand decorated biodegradable nanomedicine in the treatment of cancer. Pharmacol Res 2021;167:105544. [PMID: 33722711 DOI: 10.1016/j.phrs.2021.105544] [Reference Citation Analysis]
70 Averett C, Bhardwaj A, Arora S, Srivastava SK, Khan MA, Ahmad A, Singh S, Carter JE, Khushman M, Singh AP. Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor-stromal cross-talk. Carcinogenesis 2016;37:1052-61. [PMID: 27609457 DOI: 10.1093/carcin/bgw096] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
71 Han H, Hou Y, Chen X, Zhang P, Kang M, Jin Q, Ji J, Gao M. Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy. J Am Chem Soc 2020;142:4944-54. [PMID: 32069041 DOI: 10.1021/jacs.0c00650] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 57.0] [Reference Citation Analysis]
72 Han H, Wang H, Chen Y, Li Z, Wang Y, Jin Q, Ji J. Theranostic reduction-sensitive gemcitabine prodrug micelles for near-infrared imaging and pancreatic cancer therapy. Nanoscale 2016;8:283-91. [PMID: 26608864 DOI: 10.1039/c5nr06734k] [Cited by in Crossref: 66] [Cited by in F6Publishing: 7] [Article Influence: 13.2] [Reference Citation Analysis]
73 Hudnut AW, Lash-Rosenberg L, Xin A, Doblado JAL, Zurita-Lopez C, Wang Q, Armani AM. Role of extracellular matrix in the biomechanical behavior of pancreatic tissue. ACS Biomater Sci Eng 2018;4:1916-23. [PMID: 31828218 DOI: 10.1021/acsbiomaterials.8b00349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
74 Liu Y, Li F, Gao F, Xing L, Qin P, Liang X, Zhang J, Qiao X, Lin L, Zhao Q, Du L. Role of microenvironmental periostin in pancreatic cancer progression. Oncotarget 2017;8:89552-65. [PMID: 29163770 DOI: 10.18632/oncotarget.11533] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
75 Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed. 2014;27:1361-1370. [PMID: 25199993 DOI: 10.1002/nbm.3198] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
76 Huang Y, Lin D, Taniguchi CM. Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe? Sci China Life Sci 2017;60:1114-24. [PMID: 29039125 DOI: 10.1007/s11427-017-9178-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
77 Ceyhan GO, Friess H. Pancreatic disease in 2014: Pancreatic fibrosis and standard diagnostics. Nat Rev Gastroenterol Hepatol 2015;12:68-70. [PMID: 25560846 DOI: 10.1038/nrgastro.2014.234] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
78 Jimenez-luna C, Prados J, Ortiz R, Melguizo C, Torres C, Caba O. Current Status of Immunotherapy Treatments for Pancreatic Cancer. Journal of Clinical Gastroenterology 2016;50:836-48. [DOI: 10.1097/mcg.0000000000000623] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
79 Jiang MJ, Dai JJ, Gu DN, Huang Q, Tian L. Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Biochim Biophys Acta 2016;1866:163-76. [PMID: 27567928 DOI: 10.1016/j.bbcan.2016.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
80 Ji T, Li S, Zhang Y, Lang J, Ding Y, Zhao X, Zhao R, Li Y, Shi J, Hao J. An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer. ACS Appl Mater Interfaces. 2016;8:3438-3445. [PMID: 26759926 DOI: 10.1021/acsami.5b11619] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 15.6] [Reference Citation Analysis]
81 Lankadasari MB, Mukhopadhyay P, Mohammed S, Harikumar KB. TAMing pancreatic cancer: combat with a double edged sword. Mol Cancer 2019;18:48. [PMID: 30925924 DOI: 10.1186/s12943-019-0966-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 12.5] [Reference Citation Analysis]
82 Delitto D, Wallet SM, Hughes SJ. Targeting tumor tolerance: A new hope for pancreatic cancer therapy? Pharmacol Ther. 2016;166:9-29. [PMID: 27343757 DOI: 10.1016/j.pharmthera.2016.06.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
83 Hilmi M, Bartholin L, Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? World J Gastroenterol 2018; 24(20): 2137-2151 [PMID: 29853732 DOI: 10.3748/wjg.v24.i20.2137] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 54] [Article Influence: 21.0] [Reference Citation Analysis]
84 Masamune A, Shimosegawa T. Pancreatic stellate cells--multi-functional cells in the pancreas. Pancreatology. 2013;13:102-105. [PMID: 23561965 DOI: 10.1016/j.pan.2012.12.058] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
85 Puleo F, Maréchal R, Demetter P, Bali MA, Calomme A, Closset J, Bachet JB, Deviere J, Laethem JLV. New challenges in perioperative management of pancreatic cancer. World J Gastroenterol 2015; 21(8): 2281-2293 [PMID: 25741134 DOI: 10.3748/wjg.v21.i8.2281] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
86 Xia G, Zhang H, Cheng R, Wang H, Song Z, Deng L, Huang X, Santos HA, Cui W. Localized Controlled Delivery of Gemcitabine via Microsol Electrospun Fibers to Prevent Pancreatic Cancer Recurrence. Adv Healthcare Mater 2018;7:1800593. [DOI: 10.1002/adhm.201800593] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
87 Yuan Y, Jiang JY, Wang JM, Sun J, Li C, Liu BQ, Yan J, Meng XN, Wang HQ. BAG3-positive pancreatic stellate cells promote migration and invasion of pancreatic ductal adenocarcinoma. J Cell Mol Med 2019;23:5006-16. [PMID: 31119886 DOI: 10.1111/jcmm.14352] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
88 Hamada S, Masamune A, Shimosegawa T. Inflammation and pancreatic cancer: disease promoter and new therapeutic target. J Gastroenterol 2014;49:605-17. [DOI: 10.1007/s00535-013-0915-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
89 Xing L, Shi Q, Zheng K, Shen M, Ma J, Li F, Liu Y, Lin L, Tu W, Duan Y, Du L. Ultrasound-Mediated Microbubble Destruction (UMMD) Facilitates the Delivery of CA19-9 Targeted and Paclitaxel Loaded mPEG-PLGA-PLL Nanoparticles in Pancreatic Cancer. Theranostics 2016;6:1573-87. [PMID: 27446491 DOI: 10.7150/thno.15164] [Cited by in Crossref: 45] [Cited by in F6Publishing: 54] [Article Influence: 9.0] [Reference Citation Analysis]
90 Morvaridi S, Dhall D, Greene MI, Pandol SJ, Wang Q. Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis. Sci Rep 2015;5:16759. [PMID: 26567630 DOI: 10.1038/srep16759] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
91 Protti MP, De Monte L. Immune infiltrates as predictive markers of survival in pancreatic cancer patients. Front Physiol. 2013;4:210. [PMID: 23950747 DOI: 10.3389/fphys.2013.00210] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
92 Camus M, Vienne A, Mestas J, Pratico C, Nicco C, Chereau C, Marie J, Moussatov A, Renault G, Batteux F, Lafon C, Prat F. Cavitation-induced release of liposomal chemotherapy in orthotopic murine pancreatic cancer models: A feasibility study. Clinics and Research in Hepatology and Gastroenterology 2019;43:669-81. [DOI: 10.1016/j.clinre.2019.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Tamburrino A, Piro G, Carbone C, Tortora G, Melisi D. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol. 2013;4:56. [PMID: 23641216 DOI: 10.3389/fphar.2013.00056] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
94 Prasad S, Chandra A, Cavo M, Parasido E, Fricke S, Lee Y, D’amone E, Gigli G, Albanese C, Rodriguez O, del Mercato LL. Optical and magnetic resonance imaging approaches for investigating the tumour microenvironment: state-of-the-art review and future trends. Nanotechnology 2021;32:062001. [DOI: 10.1088/1361-6528/abc208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Khomiak A, Brunner M, Kordes M, Lindblad S, Miksch RC, Öhlund D, Regel I. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Cancers (Basel) 2020;12:E3234. [PMID: 33147766 DOI: 10.3390/cancers12113234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
96 Shabana AM, Kambhampati SP, Hsia RC, Kannan RM, Kokkoli E. Thermosensitive and biodegradable hydrogel encapsulating targeted nanoparticles for the sustained co-delivery of gemcitabine and paclitaxel to pancreatic cancer cells. Int J Pharm 2021;593:120139. [PMID: 33278494 DOI: 10.1016/j.ijpharm.2020.120139] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
97 Drifka CR, Eliceiri KW, Weber SM, Kao WJ. A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma. Lab Chip 2013;13:3965-75. [PMID: 23959166 DOI: 10.1039/c3lc50487e] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
98 Sliker BH, Campbell PM. Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment. Vaccines (Basel) 2021;9:634. [PMID: 34200702 DOI: 10.3390/vaccines9060634] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Wang J, Chai J, Liu L, Cui Z, Duan D, Shi R, Zhang Y. Dual-functional melanin-based nanoliposomes for combined chemotherapy and photothermal therapy of pancreatic cancer. RSC Adv 2019;9:3012-9. [DOI: 10.1039/c8ra09420a] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
100 Chen J, Qiu M, Zhang S, Li B, Li D, Huang X, Qian Z, Zhao J, Wang Z, Tang D. A calcium phosphate drug carrier loading with 5-fluorouracil achieving a synergistic effect for pancreatic cancer therapy. J Colloid Interface Sci 2021;605:263-73. [PMID: 34332405 DOI: 10.1016/j.jcis.2021.07.080] [Reference Citation Analysis]
101 Modica C, Tortarolo D, Comoglio PM, Basilico C, Vigna E. MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk. Int J Mol Sci 2018;19:E3920. [PMID: 30544501 DOI: 10.3390/ijms19123920] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
102 van Duijneveldt G, Griffin MDW, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin Sci (Lond) 2020;134:2091-115. [PMID: 32808663 DOI: 10.1042/CS20191211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
103 Arpalahti L, Haglund C, Holmberg CI. Proteostasis Dysregulation in Pancreatic Cancer. Adv Exp Med Biol 2020;1233:101-15. [PMID: 32274754 DOI: 10.1007/978-3-030-38266-7_4] [Reference Citation Analysis]
104 Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat Med. 2015;21:530-536. [PMID: 25894825 DOI: 10.1038/nm.3848] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 13.7] [Reference Citation Analysis]
105 Kakwere H, Ingham ES, Tumbale SK, Ferrara KW. Gemcitabine-retinoid prodrug loaded nanoparticles display in vitro antitumor efficacy towards drug-resilient human PANC-1 pancreatic cancer cells. Mater Sci Eng C Mater Biol Appl 2020;117:111251. [PMID: 32919625 DOI: 10.1016/j.msec.2020.111251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
106 Lili LN, Matyunina LV, Walker LD, Daneker GW, McDonald JF. Evidence for the importance of personalized molecular profiling in pancreatic cancer. Pancreas 2014;43:198-211. [PMID: 24518497 DOI: 10.1097/MPA.0000000000000020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
107 Muñoz AR, Chakravarthy D, Gong J, Halff GA, Ghosh R, Kumar AP. Pancreatic cancer: Current status and Challenges. Curr Pharmacol Rep 2017;3:396-408. [PMID: 29404265 DOI: 10.1007/s40495-017-0112-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
108 Zhang B, Jiang T, Shen S, She X, Tuo Y, Hu Y, Pang Z, Jiang X. Cyclopamine disrupts tumor extracellular matrix and improves the distribution and efficacy of nanotherapeutics in pancreatic cancer. Biomaterials 2016;103:12-21. [PMID: 27376555 DOI: 10.1016/j.biomaterials.2016.06.048] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
109 Zhan HX, Zhou B, Cheng YG, Xu JW, Wang L, Zhang GY, Hu SY. Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. Cancer Lett. 2017;392:83-93. [PMID: 28189533 DOI: 10.1016/j.canlet.2017.01.041] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 13.3] [Reference Citation Analysis]
110 Lee JH, Kim SK, Khawar IA, Jeong SY, Chung S, Kuh HJ. Microfluidic co-culture of pancreatic tumor spheroids with stellate cells as a novel 3D model for investigation of stroma-mediated cell motility and drug resistance. J Exp Clin Cancer Res 2018;37:4. [PMID: 29329547 DOI: 10.1186/s13046-017-0654-6] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 22.3] [Reference Citation Analysis]
111 Melamed JR, Riley RS, Valcourt DM, Day ES. Using Gold Nanoparticles To Disrupt the Tumor Microenvironment: An Emerging Therapeutic Strategy. ACS Nano 2016;10:10631-5. [PMID: 28024339 DOI: 10.1021/acsnano.6b07673] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
112 Jo Y, Choi N, Kim K, Koo HJ, Choi J, Kim HN. Chemoresistance of Cancer Cells: Requirements of Tumor Microenvironment-mimicking In Vitro Models in Anti-Cancer Drug Development. Theranostics 2018;8:5259-75. [PMID: 30555545 DOI: 10.7150/thno.29098] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 17.7] [Reference Citation Analysis]
113 Moravec R, Divi R, Verma M. Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World J Gastrointest Oncol 2017; 9(6): 235-250 [PMID: 28656074 DOI: 10.4251/wjgo.v9.i6.235] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
114 Borsoi C, Leonard F, Lee Y, Zaid M, Elganainy D, Alexander JF, Kai M, Liu YT, Kang Y, Liu X, Koay EJ, Ferrari M, Godin B, Yokoi K. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Lett 2017;403:296-304. [PMID: 28687352 DOI: 10.1016/j.canlet.2017.06.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
115 Unruh D, Ünlü B, Lewis CS, Qi X, Chu Z, Sturm R, Keil R, Ahmad SA, Sovershaev T, Adam M, Van Dreden P, Woodhams BJ, Ramchandani D, Weber GF, Rak JW, Wolberg AS, Mackman N, Versteeg HH, Bogdanov VY. Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma. Oncotarget 2016;7:25264-75. [PMID: 26967388 DOI: 10.18632/oncotarget.7955] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
116 Chronopoulos A, Lieberthal TJ, del Río Hernández AE. Pancreatic cancer: a mechanobiology approach. Converg Sci Phys Oncol 2017;3:013001. [DOI: 10.1088/2057-1739/aa5d1b] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
117 Rosati A, Basile A, D'Auria R, d'Avenia M, De Marco M, Falco A, Festa M, Guerriero L, Iorio V, Parente R, Pascale M, Marzullo L, Franco R, Arra C, Barbieri A, Rea D, Menichini G, Hahne M, Bijlsma M, Barcaroli D, Sala G, di Mola FF, di Sebastiano P, Todoric J, Antonucci L, Corvest V, Jawhari A, Firpo MA, Tuveson DA, Capunzo M, Karin M, De Laurenzi V, Turco MC. BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Nat Commun 2015;6:8695. [PMID: 26522614 DOI: 10.1038/ncomms9695] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 9.3] [Reference Citation Analysis]
118 Chen ST, Kuo TC, Liao YY, Lin MC, Tien YW, Huang MC. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway. Oncogene 2018;37:6041-53. [PMID: 29993037 DOI: 10.1038/s41388-018-0403-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
119 Moon HR, Ozcelikkale A, Yang Y, Elzey BD, Konieczny SF, Han B. An engineered pancreatic cancer model with intra-tumoral heterogeneity of driver mutations. Lab Chip 2020;20:3720-32. [PMID: 32909573 DOI: 10.1039/d0lc00707b] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
120 Peran I, Dakshanamurthy S, McCoy MD, Mavropoulos A, Allo B, Sebastian A, Hum NR, Sprague SC, Martin KA, Pishvaian MJ, Vietsch EE, Wellstein A, Atkins MB, Weiner LM, Quong AA, Loots GG, Yoo SS, Assefnia S, Byers SW. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice. Gastroenterology 2021;160:1359-1372.e13. [PMID: 33307028 DOI: 10.1053/j.gastro.2020.11.044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
121 van Manen L, Stegehuis PL, Fariña-Sarasqueta A, de Haan LM, Eggermont J, Bonsing BA, Morreau H, Lelieveldt BPF, van de Velde CJH, Vahrmeijer AL, Dijkstra J, Mieog JSD. Validation of full-field optical coherence tomography in distinguishing malignant and benign tissue in resected pancreatic cancer specimens. PLoS One 2017;12:e0175862. [PMID: 28414765 DOI: 10.1371/journal.pone.0175862] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
122 Modica C, Olivero M, Zuppini F, Milan M, Basilico C, Vigna E. HGF/MET Axis Induces Tumor Secretion of Tenascin-C and Promotes Stromal Rewiring in Pancreatic Cancer. Cancers (Basel) 2021;13:3519. [PMID: 34298732 DOI: 10.3390/cancers13143519] [Reference Citation Analysis]
123 Gong J, Xie J, Bedolla R, Rivas P, Chakravarthy D, Freeman JW, Reddick R, Kopetz S, Peterson A, Wang H. Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer. Clin Cancer Res. 2014;20:1259-1273. [PMID: 24520096 DOI: 10.1158/1078-0432.ccr-13-1664] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 6.9] [Reference Citation Analysis]
124 Abou Ali E, Bordacahar B, Mestas JL, Batteux F, Lafon C, Camus M, Prat F. Ultrasonic cavitation induces necrosis and impairs growth in three-dimensional models of pancreatic ductal adenocarcinoma. PLoS One 2018;13:e0209094. [PMID: 30596678 DOI: 10.1371/journal.pone.0209094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
125 Zhu B, Lin N, Zhang M, Zhu Y, Cheng H, Chen S, Ling Y, Pan W, Xu R. Activated hepatic stellate cells promote angiogenesis via interleukin-8 in hepatocellular carcinoma. J Transl Med. 2015;13:365. [PMID: 26593962 DOI: 10.1186/s12967-015-0730-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
126 Yu KH, Ricigliano M, Hidalgo M, Abou-Alfa GK, Lowery MA, Saltz LB, Crotty JF, Gary K, Cooper B, Lapidus R. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Clin Cancer Res. 2014;20:5281-5289. [PMID: 25107917 DOI: 10.1158/1078-0432.ccr-14-0531] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
127 Liu Y, Li F, Gao F, Xing L, Qin P, Liang X, Zhang J, Qiao X, Lin L, Zhao Q, Du L. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer. Tumour Biol 2016;37:15283-91. [PMID: 27696296 DOI: 10.1007/s13277-016-5321-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
128 Jena BC, Rout L, Dey A, Mandal M. Active autophagy in cancer-associated fibroblasts: Recent advances in understanding the novel mechanism of tumor progression and therapeutic response. J Cell Physiol 2021. [PMID: 34008184 DOI: 10.1002/jcp.30419] [Reference Citation Analysis]
129 Young SJ. Irreversible electroporation and the pancreas: What we know and where we are going? World J Gastrointest Surg 2015; 7(8): 138-144 [PMID: 26328033 DOI: 10.4240/wjgs.v7.i8.138] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
130 Sonohara F, Goel A. Features of Immune Cells and the Tumor-Associated Stroma Tango as Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma. Gastroenterology 2018;155:1312-4. [PMID: 30300611 DOI: 10.1053/j.gastro.2018.10.008] [Reference Citation Analysis]
131 Jiang H, Hegde S, DeNardo DG. Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. Cancer Immunol Immunother 2017;66:1037-48. [PMID: 28451791 DOI: 10.1007/s00262-017-2003-1] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 21.0] [Reference Citation Analysis]
132 Kozak G, Blanco FF, Brody JR. Novel Targets in Pancreatic Cancer Research. Seminars in Oncology 2015;42:177-87. [DOI: 10.1053/j.seminoncol.2014.12.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
133 He X, Chen X, Liu L, Zhang Y, Lu Y, Zhang Y, Chen Q, Ruan C, Guo Q, Li C, Sun T, Jiang C. Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy. Adv Sci (Weinh) 2018;5:1701070. [PMID: 29876225 DOI: 10.1002/advs.201701070] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
134 Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol 2017;24:311-35. [PMID: 28777143 DOI: 10.1097/PAP.0000000000000161] [Cited by in Crossref: 220] [Cited by in F6Publishing: 146] [Article Influence: 73.3] [Reference Citation Analysis]
135 Masamune A, Hamada S, Kikuta K, Takikawa T, Miura S, Nakano E, Shimosegawa T. The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scand J Gastroenterol. 2013;48:602-609. [PMID: 23477656 DOI: 10.3109/00365521.2013.777776] [Cited by in Crossref: 45] [Cited by in F6Publishing: 75] [Article Influence: 5.6] [Reference Citation Analysis]
136 Parekh HD, Starr J, George TJ Jr. The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. Curr Treat Options Oncol 2017;18:73. [PMID: 29143898 DOI: 10.1007/s11864-017-0515-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
137 Wang J, Zhang Y, Liu L, Cui Z, Liu X, Wang L, Li Y, Li Q. Combined chemo/photothermal therapy based on mesoporous silica-Au core-shell nanoparticles for hepatocellular carcinoma treatment. Drug Dev Ind Pharm 2019;45:1487-95. [PMID: 31172835 DOI: 10.1080/03639045.2019.1629688] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
138 Han H, Valdepérez D, Jin Q, Yang B, Li Z, Wu Y, Pelaz B, Parak WJ, Ji J. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy. ACS Nano 2017;11:1281-91. [DOI: 10.1021/acsnano.6b05541] [Cited by in Crossref: 107] [Cited by in F6Publishing: 100] [Article Influence: 26.8] [Reference Citation Analysis]
139 Mukundan S, Sharma K, Honselmann K, Singleton A, Liss A, Parekkadan B. Image-Based Profiling of Patient-Derived Pancreatic Tumor-Stromal Cell Interactions Within a Micropatterned Tumor Model. Technol Cancer Res Treat 2018;17:1533033818803632. [PMID: 30348057 DOI: 10.1177/1533033818803632] [Reference Citation Analysis]
140 Procacci P, Moscheni C, Sartori P, Sommariva M, Gagliano N. Tumor⁻Stroma Cross-Talk in Human Pancreatic Ductal Adenocarcinoma: A Focus on the Effect of the Extracellular Matrix on Tumor Cell Phenotype and Invasive Potential. Cells 2018;7:E158. [PMID: 30301152 DOI: 10.3390/cells7100158] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
141 Leca J, Martinez S, Lac S, Nigri J, Secq V, Rubis M, Bressy C, Sergé A, Lavaut MN, Dusetti N, Loncle C, Roques J, Pietrasz D, Bousquet C, Garcia S, Granjeaud S, Ouaissi M, Bachet JB, Brun C, Iovanna JL, Zimmermann P, Vasseur S, Tomasini R. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. J Clin Invest 2016;126:4140-56. [PMID: 27701147 DOI: 10.1172/JCI87734] [Cited by in Crossref: 107] [Cited by in F6Publishing: 75] [Article Influence: 21.4] [Reference Citation Analysis]
142 Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther. 2013;7:33-43. [PMID: 24379681 DOI: 10.2147/ott.s38111] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
143 Li Y, Zhao Z, Lin CY, Liu Y, Staveley-OCarroll KF, Li G, Cheng K. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer. Theranostics 2021;11:2182-200. [PMID: 33500719 DOI: 10.7150/thno.53102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
144 Wang Y, Gao Z, Du X, Chen S, Zhang W, Wang J, Li H, He X, Cao J, Wang J. Co-inhibition of the TGF-β pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy. Biomater Sci 2020;8:5121-32. [PMID: 32820750 DOI: 10.1039/d0bm00916d] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
145 Ligorio M, Sil S, Malagon-Lopez J, Nieman LT, Misale S, Di Pilato M, Ebright RY, Karabacak MN, Kulkarni AS, Liu A, Vincent Jordan N, Franses JW, Philipp J, Kreuzer J, Desai N, Arora KS, Rajurkar M, Horwitz E, Neyaz A, Tai E, Magnus NKC, Vo KD, Yashaswini CN, Marangoni F, Boukhali M, Fatherree JP, Damon LJ, Xega K, Desai R, Choz M, Bersani F, Langenbucher A, Thapar V, Morris R, Wellner UF, Schilling O, Lawrence MS, Liss AS, Rivera MN, Deshpande V, Benes CH, Maheswaran S, Haber DA, Fernandez-Del-Castillo C, Ferrone CR, Haas W, Aryee MJ, Ting DT. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Cell 2019;178:160-175.e27. [PMID: 31155233 DOI: 10.1016/j.cell.2019.05.012] [Cited by in Crossref: 143] [Cited by in F6Publishing: 148] [Article Influence: 71.5] [Reference Citation Analysis]
146 Li T, Wang YN, Khokhlova TD, D'Andrea S, Starr F, Chen H, McCune JS, Risler LJ, Mashadi-Hossein A, Hingorani SR, Chang A, Hwang JH. Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer. Cancer Res. 2015;75:3738-3746. [PMID: 26216548 DOI: 10.1158/0008-5472.can-15-0296] [Cited by in Crossref: 41] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
147 Madamsetty VS, Pal K, Keshavan S, Caulfield TR, Dutta SK, Wang E, Fadeel B, Mukhopadhyay D. Development of multi-drug loaded PEGylated nanodiamonds to inhibit tumor growth and metastasis in genetically engineered mouse models of pancreatic cancer. Nanoscale 2019;11:22006-18. [PMID: 31710073 DOI: 10.1039/c9nr05478b] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 17.0] [Reference Citation Analysis]
148 Takeya M, Komohara Y. Role of tumor-associated macrophages in human malignancies: friend or foe? Pathol Int 2016;66:491-505. [PMID: 27444136 DOI: 10.1111/pin.12440] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 17.0] [Reference Citation Analysis]
149 Delitto D, Perez C, Han S, Gonzalo DH, Pham K, Knowlton AE, Graves CL, Behrns KE, Moldawer LL, Thomas RM, Liu C, George TJ Jr, Trevino JG, Wallet SM, Hughes SJ. Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer. Cancer Immunol Immunother 2015;64:1553-63. [PMID: 26423423 DOI: 10.1007/s00262-015-1760-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
150 Yang M, Yan Z, Luo J, Liu Q, Zhang W, Ma J, Zhang Z, Yu T, Zhao Q, Liu L. A pilot study of intraluminal brachytherapy using 125I seed strand for locally advanced pancreatic ductal adenocarcinoma with obstructive jaundice. Brachytherapy. 2016;15:859-864. [PMID: 27364870 DOI: 10.1016/j.brachy.2016.05.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
151 Delitto D, Delitto AE, DiVita BB, Pham K, Han S, Hartlage ER, Newby BN, Gerber MH, Behrns KE, Moldawer LL, Thomas RM, George TJ Jr, Brusko TM, Mathews CE, Liu C, Trevino JG, Hughes SJ, Wallet SM. Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. Cancer Res 2017;77:672-83. [PMID: 27864347 DOI: 10.1158/0008-5472.CAN-16-1765] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
152 Lee J, Snyder ER, Liu Y, Gu X, Wang J, Flowers BM, Kim YJ, Park S, Szot GL, Hruban RH, Longacre TA, Kim SK. Reconstituting development of pancreatic intraepithelial neoplasia from primary human pancreas duct cells. Nat Commun 2017;8:14686. [PMID: 28272465 DOI: 10.1038/ncomms14686] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
153 Xie Y, Hang Y, Wang Y, Sleightholm R, Prajapati DR, Bader J, Yu A, Tang W, Jaramillo L, Li J, Singh RK, Oupický D. Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy. ACS Nano 2020;14:255-71. [PMID: 31927946 DOI: 10.1021/acsnano.9b03978] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 23.0] [Reference Citation Analysis]
154 Mu W, Rana S, Zöller M. Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia 2013;15:875-87. [PMID: 23908589 DOI: 10.1593/neo.13786] [Cited by in Crossref: 136] [Cited by in F6Publishing: 140] [Article Influence: 19.4] [Reference Citation Analysis]
155 Pfohl U, Pflaume A, Regenbrecht M, Finkler S, Graf Adelmann Q, Reinhard C, Regenbrecht CRA, Wedeken L. Precision Oncology Beyond Genomics: The Future Is Here-It Is Just Not Evenly Distributed. Cells 2021;10:928. [PMID: 33920536 DOI: 10.3390/cells10040928] [Reference Citation Analysis]
156 Shi H, Li J, Fu D. Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. J Cancer Res Clin Oncol 2016;142:1137-61. [PMID: 26250876 DOI: 10.1007/s00432-015-2024-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
157 Ren B, Yang J, Wang C, Yang G, Wang H, Chen Y, Xu R, Fan X, You L, Zhang T, Zhao Y. High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis. J Hematol Oncol 2021;14:120. [PMID: 34348759 DOI: 10.1186/s13045-021-01131-0] [Reference Citation Analysis]
158 Yuen A, Díaz B. The impact of hypoxia in pancreatic cancer invasion and metastasis. Hypoxia (Auckl) 2014;2:91-106. [PMID: 27774469 DOI: 10.2147/HP.S52636] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
159 Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S, Qiao Y. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther 2021;6:153. [PMID: 33888679 DOI: 10.1038/s41392-021-00544-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
160 Burkhardt C, Tzschätzsch H, Schmuck R, Bahra M, Jürgensen C, Pelzer U, Hamm B, Braun J, Sack I, Marticorena Garcia SR. Ultrasound Time-Harmonic Elastography of the Pancreas: Reference Values and Clinical Feasibility. Investigative Radiology 2020;55:270-6. [DOI: 10.1097/rli.0000000000000638] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
161 Cramer GM, Jones DP, El-Hamidi H, Celli JP. ECM Composition and Rheology Regulate Growth, Motility, and Response to Photodynamic Therapy in 3D Models of Pancreatic Ductal Adenocarcinoma. Mol Cancer Res 2017;15:15-25. [PMID: 27671335 DOI: 10.1158/1541-7786.MCR-16-0260] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
162 Kolodecik T, Shugrue C, Ashat M, Thrower EC. Risk factors for pancreatic cancer: underlying mechanisms and potential targets. Front Physiol 2013;4:415. [PMID: 24474939 DOI: 10.3389/fphys.2013.00415] [Cited by in Crossref: 27] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
163 Baek G, Tse YF, Hu Z, Cox D, Buboltz N, McCue P, Yeo CJ, White MA, DeBerardinis RJ, Knudsen ES, Witkiewicz AK. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep 2014;9:2233-49. [PMID: 25497091 DOI: 10.1016/j.celrep.2014.11.025] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 15.6] [Reference Citation Analysis]
164 Meng H, Wang M, Liu H, Liu X, Situ A, Wu B, Ji Z, Chang CH, Nel AE. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano. 2015;9:3540-3557. [PMID: 25776964 DOI: 10.1021/acsnano.5b00510] [Cited by in Crossref: 254] [Cited by in F6Publishing: 230] [Article Influence: 42.3] [Reference Citation Analysis]
165 Hazama S, Tamada K, Yamaguchi Y, Kawakami Y, Nagano H. Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Ann Gastroenterol Surg. 2018;2:289-303. [PMID: 30003192 DOI: 10.1002/ags3.12180] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
166 Folch-Puy E. REG3β contributes to the immunosuppressive microenvironment of pancreatic cancer. Oncoimmunology 2013;2:e26404. [PMID: 24353919 DOI: 10.4161/onci.26404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
167 Kokkinos J, Jensen A, Sharbeen G, McCarroll JA, Goldstein D, Haghighi KS, Phillips PA. Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer? Cancers (Basel) 2021;13:2427. [PMID: 34067833 DOI: 10.3390/cancers13102427] [Reference Citation Analysis]
168 Karnevi E, Rosendahl AH, Hilmersson KS, Saleem MA, Andersson R. Impact by pancreatic stellate cells on epithelial-mesenchymal transition and pancreatic cancer cell invasion: Adding a third dimension in vitro. Exp Cell Res 2016;346:206-15. [PMID: 27443257 DOI: 10.1016/j.yexcr.2016.07.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
169 Romero EL, Morilla MJ. Preclinical autophagy modulatory nanomedicines: big challenges, slow advances. Expert Opin Drug Deliv 2021;:1-19. [PMID: 34030559 DOI: 10.1080/17425247.2021.1933428] [Reference Citation Analysis]
170 Liu X, Li Z, Wang Y. Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. Adv Biol (Weinh) 2021;5:e1900236. [PMID: 33729700 DOI: 10.1002/adbi.201900236] [Reference Citation Analysis]
171 Zhou H, Qian W, Uckun FM, Wang L, Wang YA, Chen H, Kooby D, Yu Q, Lipowska M, Staley CA, Mao H, Yang L. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer. ACS Nano 2015;9:7976-91. [PMID: 26242412 DOI: 10.1021/acsnano.5b01288] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 13.3] [Reference Citation Analysis]
172 Bahrami A, Khazaei M, Bagherieh F, Ghayour-Mobarhan M, Maftouh M, Hassanian SM, Avan A. Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies. J Cell Physiol. 2017;232:2931-2937. [PMID: 28083912 DOI: 10.1002/jcp.25798] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
173 Rai ZL, Feakins R, Pallett LJ, Manas D, Davidson BR. Irreversible Electroporation (IRE) in Locally Advanced Pancreatic Cancer: A Review of Current Clinical Outcomes, Mechanism of Action and Opportunities for Synergistic Therapy. J Clin Med 2021;10:1609. [PMID: 33920118 DOI: 10.3390/jcm10081609] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Hoang NT, Kadonosono T, Kuchimaru T, Kizaka-Kondoh S. Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model. Cancer Sci 2016;107:1151-8. [PMID: 27270607 DOI: 10.1111/cas.12982] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
175 Cho SY, Lee TH, Ku YH, Kim HI, Lee GH, Kim MJ. Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia. Surgery 2015;157:111-8. [DOI: 10.1016/j.surg.2014.05.023] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
176 Yan Y, Chen X, Wang X, Zhao Z, Hu W, Zeng S, Wei J, Yang X, Qian L, Zhou S, Sun L, Gong Z, Xu Z. The effects and the mechanisms of autophagy on the cancer-associated fibroblasts in cancer. J Exp Clin Cancer Res 2019;38:171. [PMID: 31014370 DOI: 10.1186/s13046-019-1172-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 16.5] [Reference Citation Analysis]
177 Cortes E, Sarper M, Robinson B, Lachowski D, Chronopoulos A, Thorpe SD, Lee DA, Del Río Hernández AE. GPER is a mechanoregulator of pancreatic stellate cells and the tumor microenvironment. EMBO Rep 2019;20:e46556. [PMID: 30538117 DOI: 10.15252/embr.201846556] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
178 Yalçın S, Erkan M, Ünsoy G, Parsian M, Kleeff J, Gündüz U. Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines. Biomedicine & Pharmacotherapy 2014;68:737-43. [DOI: 10.1016/j.biopha.2014.07.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
179 Chen X, Teng W, Jin Q, Ji J. One-step preparation of reduction-responsive cross-linked gemcitabine prodrug micelles for intracellular drug delivery. Colloids and Surfaces B: Biointerfaces 2019;181:94-101. [DOI: 10.1016/j.colsurfb.2019.05.038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
180 Ebelt ND, Zuniga E, Passi KB, Sobocinski LJ, Manuel ER. Hyaluronidase-Expressing Salmonella Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther 2020;19:706-16. [PMID: 31694889 DOI: 10.1158/1535-7163.MCT-19-0556] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
181 Mielgo A, Schmid MC. Impact of tumour associated macrophages in pancreatic cancer. BMB Rep 2013;46:131-8. [PMID: 23527856 DOI: 10.5483/bmbrep.2013.46.3.036] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
182 Pitarresi JR, Liu X, Sharma SM, Cuitiño MC, Kladney RD, Mace TA, Donohue S, Nayak SG, Qu C, Lee J, Woelke SA, Trela S, LaPak K, Yu L, McElroy J, Rosol TJ, Shakya R, Ludwig T, Lesinski GB, Fernandez SA, Konieczny SF, Leone G, Wu J, Ostrowski MC. Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia. Neoplasia 2016;18:541-52. [PMID: 27659014 DOI: 10.1016/j.neo.2016.07.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
183 Han S, Raijman I, Machicado JD, Edmundowicz SA, Shah RJ. Per Oral Pancreatoscopy Identification of Main-duct Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Duct Stones: Not Mutually Exclusive. Pancreas 2019;48:792-4. [PMID: 31210658 DOI: 10.1097/MPA.0000000000001333] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
184 Sandini M, Negreros-Osuna AA, Qadan M, Hank T, Patino M, Ferrone CR, Warshaw AL, Lillemoe KD, Sahani D, Castillo CF. Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. Ann Surg Oncol. 2019;. [PMID: 31722071 DOI: 10.1245/s10434-019-08040-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
185 Ahmad RS, Eubank TD, Lukomski S, Boone BA. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer. Biomolecules 2021;11:901. [PMID: 34204306 DOI: 10.3390/biom11060901] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
186 Wang Y, Ni Q, Sun J, Xu M, Xie J, Zhang J, Fang Y, Ning G, Wang Q. Paraneoplastic β Cell Dedifferentiation in Nondiabetic Patients with Pancreatic Cancer. J Clin Endocrinol Metab 2020;105:dgz224. [PMID: 31781763 DOI: 10.1210/clinem/dgz224] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
187 Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2014;13:2583-2594. [PMID: 25193509 DOI: 10.1158/1535-7163.mct-14-0028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
188 Nakai Y, Isayama H, Ijichi H, Sasaki T, Takahara N, Ito Y, Matsubara S, Uchino R, Yagioka H, Arizumi T, Hamada T, Miyabayashi K, Mizuno S, Yamamoto K, Kogure H, Yamamoto N, Hirano K, Sasahira N, Tateishi K, Tada M, Koike K. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Invest New Drugs 2013;31:1294-9. [PMID: 23690239 DOI: 10.1007/s10637-013-9972-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
189 Ware MJ, Keshishian V, Law JJ, Ho JC, Favela CA, Rees P, Smith B, Mohammad S, Hwang RF, Rajapakshe K, Coarfa C, Huang S, Edwards DP, Corr SJ, Godin B, Curley SA. Generation of an in vitro 3D PDAC stroma rich spheroid model. Biomaterials 2016;108:129-42. [PMID: 27627810 DOI: 10.1016/j.biomaterials.2016.08.041] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 13.0] [Reference Citation Analysis]
190 Jiang B, Zhou L, Lu J, Wang Y, Liu C, You L, Guo J. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?Front Oncol. 2020;10:576399. [PMID: 33178608 DOI: 10.3389/fonc.2020.576399] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
191 Nobis M, McGhee EJ, Herrmann D, Magenau A, Morton JP, Anderson KI, Timpson P. Monitoring the dynamics of Src activity in response to anti-invasive dasatinib treatment at a subcellular level using dual intravital imaging. Cell Adh Migr 2014;8:478-86. [PMID: 25482620 DOI: 10.4161/19336918.2014.970004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
192 Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019;18:14. [PMID: 30665410 DOI: 10.1186/s12943-018-0927-5] [Cited by in Crossref: 93] [Cited by in F6Publishing: 92] [Article Influence: 46.5] [Reference Citation Analysis]
193 Klett H, Fuellgraf H, Levit-Zerdoun E, Hussung S, Kowar S, Küsters S, Bronsert P, Werner M, Wittel U, Fritsch R, Busch H, Boerries M. Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma. Front Genet 2018;9:108. [PMID: 29675033 DOI: 10.3389/fgene.2018.00108] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
194 Kandimalla R, Tomihara H, Banwait JK, Yamamura K, Singh G, Baba H, Goel A. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26:3641-8. [PMID: 32234757 DOI: 10.1158/1078-0432.CCR-19-4044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
195 Anbil S, Pigula M, Huang HC, Mallidi S, Broekgaarden M, Baglo Y, De Silva P, Simeone DM, Mino-Kenudson M, Maytin EV, Rizvi I, Hasan T. Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy. Mol Cancer Ther 2020;19:1308-19. [PMID: 32220968 DOI: 10.1158/1535-7163.MCT-19-0791] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
196 Li Y, Zhao Z, Liu H, Fetse JP, Jain A, Lin CY, Cheng K. Development of a Tumor-Responsive Nanopolyplex Targeting Pancreatic Cancer Cells and Stroma. ACS Appl Mater Interfaces 2019;11:45390-403. [PMID: 31769963 DOI: 10.1021/acsami.9b15116] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
197 Pan H, Diao H, Zhong W, Wang T, Wen P, Wu C. A Cancer Cell Cluster Marked by LincRNA MEG3 Leads Pancreatic Ductal Adenocarcinoma Metastasis. Front Oncol 2021;11:656564. [PMID: 34055623 DOI: 10.3389/fonc.2021.656564] [Reference Citation Analysis]
198 Mathison A, Grzenda A, Lomberk G, Velez G, Buttar N, Tietz P, Hendrickson H, Liebl A, Xiong YY, Gores G, Fernandez-Zapico M, Larusso NF, Faubion W, Shah VH, Urrutia R. Role for Krüppel-like transcription factor 11 in mesenchymal cell function and fibrosis. PLoS One 2013;8:e75311. [PMID: 24069400 DOI: 10.1371/journal.pone.0075311] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
199 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
200 Neuzillet C, Rousseau B, Kocher H, Bourget P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. Pharmacol Ther. 2017;174:145-172. [PMID: 28223233 DOI: 10.1016/j.pharmthera.2017.02.028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
201 Hadden M, Mittal A, Samra J, Zreiqat H, Sahni S, Ramaswamy Y. Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression.BiochimBiophysActa Rev Cancer. 2020;1874:188418. [PMID: 32827581 DOI: 10.1016/j.bbcan.2020.188418] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
202 Saison-Ridinger M, DelGiorno KE, Zhang T, Kraus A, French R, Jaquish D, Tsui C, Erikson G, Spike BT, Shokhirev MN, Liddle C, Yu RT, Downes M, Evans RM, Saghatelian A, Lowy AM, Wahl GM. Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy. PLoS One 2017;12:e0189051. [PMID: 29211796 DOI: 10.1371/journal.pone.0189051] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
203 Wang Y, Jin G, Li Q, Wang Z, Hu W, Li P, Li S, Wu H, Kong X, Gao J, Li Z. Hedgehog Signaling Non-Canonical Activated by Pro-Inflammatory Cytokines in Pancreatic Ductal Adenocarcinoma. J Cancer 2016;7:2067-76. [PMID: 27877222 DOI: 10.7150/jca.15786] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
204 Hu H, Jiao F, Han T, Wang LW. Functional significance of macrophages in pancreatic cancer biology. Tumour Biol. 2015;36:9119-9126. [PMID: 26411672 DOI: 10.1007/s13277-015-4127-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
205 McCarroll J, Teo J, Boyer C, Goldstein D, Kavallaris M, Phillips PA. Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front Physiol 2014;5:2. [PMID: 24478715 DOI: 10.3389/fphys.2014.00002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
206 Damhofer H, Medema JP, Veenstra VL, Badea L, Popescu I, Roelink H, Bijlsma MF. Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma. Mol Oncol. 2013;7:1031-1042. [PMID: 23998958 DOI: 10.1016/j.molonc.2013.08.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
207 Li Y, Hong J, Oh JE, Yoon AR, Yun CO. Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer. Int J Cancer 2018;142:392-413. [PMID: 28929492 DOI: 10.1002/ijc.31060] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
208 Sakai S, Iwata C, Tanaka HY, Cabral H, Morishita Y, Miyazono K, Kano MR. Increased fibrosis and impaired intratumoral accumulation of macromolecules in a murine model of pancreatic cancer co-administered with FGF-2. J Control Release 2016;230:109-15. [PMID: 27080571 DOI: 10.1016/j.jconrel.2016.04.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
209 Lee SY, Lloyd WR, Chandra M, Wilson RH, McKenna B, Simeone D, Scheiman J, Mycek MA. Characterizing human pancreatic cancer precursor using quantitative tissue optical spectroscopy. Biomed Opt Express 2013;4:2828-34. [PMID: 24409383 DOI: 10.1364/BOE.4.002828] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
210 Fan YF, Shang WT, Lu GH, Guo KX, Deng H, Zhu XH, Wang CC, Tian J. Decreasing hyaluronic acid combined with drug-loaded nanoprobes improve the delivery and efficacy of chemotherapeutic drugs for pancreatic cancer. Cancer Lett 2021;523:1-9. [PMID: 34530049 DOI: 10.1016/j.canlet.2021.09.016] [Reference Citation Analysis]
211 Alzhrani R, Alsaab HO, Vanamal K, Bhise K, Tatiparti K, Barari A, Sau S, Iyer AK. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Adv Ther (Weinh) 2021;4:2000262. [PMID: 34212073 DOI: 10.1002/adtp.202000262] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
212 Ferdek PE, Jakubowska MA. Biology of pancreatic stellate cells-more than just pancreatic cancer. Pflugers Arch 2017;469:1039-50. [PMID: 28382480 DOI: 10.1007/s00424-017-1968-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 10.8] [Reference Citation Analysis]
213 Li M, Xie H, Liu Y, Xia C, Cun X, Long Y, Chen X, Deng M, Guo R, Zhang Z, He Q. Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer. J Control Release 2019;304:204-15. [PMID: 31100311 DOI: 10.1016/j.jconrel.2019.05.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 17.0] [Reference Citation Analysis]
214 Okada K, Hirono S, Kawai M, Miyazawa M, Shimizu A, Kitahata Y, Ueno M, Hayami S, Kojima F, Yamaue H. Value of apparent diffusion coefficient prior to neoadjuvant therapy is a predictor of histologic response in patients with borderline resectable pancreatic carcinoma. J Hepatobiliary Pancreat Sci 2017;24:161-8. [DOI: 10.1002/jhbp.430] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
215 Kibe S, Ohuchida K, Ando Y, Takesue S, Nakayama H, Abe T, Endo S, Koikawa K, Okumura T, Iwamoto C, Shindo K, Moriyama T, Nakata K, Miyasaka Y, Shimamoto M, Ohtsuka T, Mizumoto K, Oda Y, Nakamura M. Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion. Cancer Lett 2019;444:70-81. [PMID: 30590101 DOI: 10.1016/j.canlet.2018.12.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
216 Matsuo Y, Ding Q, Desaki R, Maemura K, Mataki Y, Shinchi H, Natsugoe S, Takao S. Hypoxia inducible factor-1 alpha plays a pivotal role in hepatic metastasis of pancreatic cancer: an immunohistochemical study. J Hepatobiliary Pancreat Sci 2014;21:105-12. [DOI: 10.1002/jhbp.6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
217 Liang C, Shi S, Meng Q, Liang D, Ji S, Zhang B, Qin Y, Xu J, Ni Q, Yu X. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer? Cell Mol Life Sci 2018;75:1001-12. [DOI: 10.1007/s00018-017-2678-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
218 Wong AD, Russell LM, Katt ME, Searson PC. Chemotherapeutic Drug Delivery and Quantitative Analysis of Proliferation, Apoptosis, and Migration in a Tissue-Engineered Three-Dimensional Microvessel Model of the Tumor Microenvironment. ACS Biomater Sci Eng 2019;5:633-43. [DOI: 10.1021/acsbiomaterials.8b00877] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
219 Wiley SZ, Sriram K, Liang W, Chang SE, French R, McCann T, Sicklick J, Nishihara H, Lowy AM, Insel PA. GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells. FASEB J 2018;32:1170-83. [PMID: 29092903 DOI: 10.1096/fj.201700834R] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 13.7] [Reference Citation Analysis]
220 Xie B, Hänsel J, Mundorf V, Betz J, Reimche I, Erkan M, Büdeyri I, Gesell A, Kerr RG, Ariantari NP, Yu H, Proksch P, Teusch N, Mrsny RJ. Pseudopterosin and O-Methyltylophorinidine Suppress Cell Growth in a 3D Spheroid Co-Culture Model of Pancreatic Ductal Adenocarcinoma. Bioengineering (Basel) 2020;7:E57. [PMID: 32545910 DOI: 10.3390/bioengineering7020057] [Reference Citation Analysis]
221 Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, Zhao F, You L, Zheng L, Zhang T, Zhao Y. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol 2021;14:14. [PMID: 33436044 DOI: 10.1186/s13045-020-01030-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
222 Almawash SA, Mondal G, Mahato RI. Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis. Pharm Res 2018;35:17. [PMID: 29305793 DOI: 10.1007/s11095-017-2303-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
223 Nikfarjam M, Yeo D, He H, Baldwin G, Fifis T, Costa P, Tan B, Yang E, Wen Sw, Christophi C. Comparison of two syngeneic orthotopic murine models of pancreatic adenocarcinoma. J Invest Surg 2013;26:352-9. [PMID: 23957638 DOI: 10.3109/08941939.2013.797057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
224 Yang D, Shi J, Fu H, Wei Z, Xu J, Hu Z, Zhang Y, Yan R, Cai Q. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas. Tumour Biol 2016;37:12315-27. [PMID: 27289231 DOI: 10.1007/s13277-016-5061-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
225 Hu Y, Chi C, Wang S, Wang L, Liang P, Liu F, Shang W, Wang W, Zhang F, Li S, Shen H, Yu X, Liu H, Tian J. A Comparative Study of Clinical Intervention and Interventional Photothermal Therapy for Pancreatic Cancer. Adv Mater 2017;29:1700448. [DOI: 10.1002/adma.201700448] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
226 Matsumoto S, Kishimoto S, Saito K, Takakusagi Y, Munasinghe JP, Devasahayam N, Hart CP, Gillies RJ, Mitchell JB, Krishna MC. Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice. Cancer Res 2018;78:3783-92. [PMID: 29792309 DOI: 10.1158/0008-5472.CAN-18-0491] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
227 Polasek M, Yang Y, Schühle DT, Yaseen MA, Kim YR, Sung YS, Guimaraes AR, Caravan P. Molecular MR imaging of fibrosis in a mouse model of pancreatic cancer. Sci Rep 2017;7:8114. [PMID: 28808290 DOI: 10.1038/s41598-017-08838-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
228 Nishida Y, Nagatsuma AK, Kojima M, Gotohda N, Ochiai A. Novel stromal biomarker screening in pancreatic cancer patients using the in vitro cancer-stromal interaction model. BMC Gastroenterol 2020;20:411. [PMID: 33297976 DOI: 10.1186/s12876-020-01556-w] [Reference Citation Analysis]
229 Bronsert P, Kohler I, Timme S, Kiefer S, Werner M, Schilling O, Vashist Y, Makowiec F, Brabletz T, Hopt UT. Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer. Surgery. 2014;156:97-108. [PMID: 24929761 DOI: 10.1016/j.surg.2014.02.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 6.7] [Reference Citation Analysis]
230 Fan F, Jin L, Yang L. pH-Sensitive Nanoparticles Composed Solely of Membrane-Disruptive Macromolecules for Treating Pancreatic Cancer. ACS Appl Mater Interfaces 2021;13:12824-35. [PMID: 33689289 DOI: 10.1021/acsami.0c16576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Aghamiri S, Raee P, Talaei S, Mohammadi-Yeganeh S, Bayat S, Rezaee D, Ghavidel AA, Teymouri A, Roshanzamiri S, Farhadi S, Ghanbarian H. Nonviral siRNA delivery systems for pancreatic cancer therapy. Biotechnol Bioeng 2021. [PMID: 34170520 DOI: 10.1002/bit.27869] [Reference Citation Analysis]
232 Lu G, Shang W, Deng H, Han Z, Hu M, Liang X, Fang C, Zhu X, Fan Y, Tian J. Targeting carbon nanotubes based on IGF-1R for photothermal therapy of orthotopic pancreatic cancer guided by optical imaging. Biomaterials 2019;195:13-22. [DOI: 10.1016/j.biomaterials.2018.12.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 24.0] [Reference Citation Analysis]
233 Minami K, Jimbo N, Tanaka Y, Uchida T, Okamoto T, Shimizu N, Doi T, Hokka D, Itoh T, Maniwa Y. Fibrous bands associated with higher Masaoka stage and poor recurrence-free survival in patients with thymoma. Thorac Cancer 2021;12:349-56. [PMID: 33236521 DOI: 10.1111/1759-7714.13755] [Reference Citation Analysis]
234 Erkan M. The role of pancreatic stellate cells in pancreatic cancer. Pancreatology 2013;13:106-9. [PMID: 23561966 DOI: 10.1016/j.pan.2013.01.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
235 Bi Y, Li J, Ji B, Kang N, Yang L, Simonetto DA, Kwon JH, Kamath M, Cao S, Shah V. Sphingosine-1-phosphate mediates a reciprocal signaling pathway between stellate cells and cancer cells that promotes pancreatic cancer growth. Am J Pathol 2014;184:2791-802. [PMID: 25111230 DOI: 10.1016/j.ajpath.2014.06.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
236 Jauset T, Massó-Vallés D, Martínez-Martín S, Beaulieu ME, Foradada L, Fiorentino FP, Yokota J, Haendler B, Siegel S, Whitfield JR, Soucek L. BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. Oncotarget 2018;9:18734-46. [PMID: 29721157 DOI: 10.18632/oncotarget.24648] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
237 Drifka CR, Tod J, Loeffler AG, Liu Y, Thomas GJ, Eliceiri KW, Kao WJ. Periductal stromal collagen topology of pancreatic ductal adenocarcinoma differs from that of normal and chronic pancreatitis. Mod Pathol 2015;28:1470-80. [DOI: 10.1038/modpathol.2015.97] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
238 Montesi SB, Désogère P, Fuchs BC, Caravan P. Molecular imaging of fibrosis: recent advances and future directions. J Clin Invest 2019;129:24-33. [PMID: 30601139 DOI: 10.1172/JCI122132] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 22.0] [Reference Citation Analysis]
239 Ji Y, Liu X, Li J, Xie X, Huang M, Jiang J, Liao YP, Donahue T, Meng H. Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment. Nat Commun 2020;11:4249. [PMID: 32843618 DOI: 10.1038/s41467-020-17996-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
240 Chitiboi T, Muckley M, Dane B, Huang C, Feng L, Chandarana H. Pancreas deformation in the presence of tumors using feature tracking from free-breathing XD-GRASP MRI. J Magn Reson Imaging 2019;50:1633-40. [PMID: 30854767 DOI: 10.1002/jmri.26714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
241 Li XY, Tao H, Jin C, DU ZY, Liao WF, Tang QJ, Ding K. Cordycepin inhibits pancreatic cancer cell growth in vitro and in vivo via targeting FGFR2 and blocking ERK signaling. Chin J Nat Med 2020;18:345-55. [PMID: 32451092 DOI: 10.1016/S1875-5364(20)30041-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, van IJcken WF, Heine AA, Smid M, Koudijs MJ, Brenton JD, Berns EM, Helleman J. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One 2014;9:e103988. [PMID: 25230021 DOI: 10.1371/journal.pone.0103988] [Cited by in Crossref: 201] [Cited by in F6Publishing: 190] [Article Influence: 28.7] [Reference Citation Analysis]
243 Yang S, Gao H. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharmacol Res 2017;126:97-108. [PMID: 28501517 DOI: 10.1016/j.phrs.2017.05.004] [Cited by in Crossref: 101] [Cited by in F6Publishing: 98] [Article Influence: 25.3] [Reference Citation Analysis]
244 Jiang JH, Liu C, Cheng H, Lu Y, Qin Y, Xu YF, Xu J, Long J, Liu L, Ni QX. Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor? Biochim Biophys Acta. 2015;1855:43-49. [PMID: 25432020 DOI: 10.1016/j.bbcan.2014.11.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
245 Adjuto-Saccone M, Soubeyran P, Garcia J, Audebert S, Camoin L, Rubis M, Roques J, Binétruy B, Iovanna JL, Tournaire R. TNF-α induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma. Cell Death Dis 2021;12:649. [PMID: 34172716 DOI: 10.1038/s41419-021-03920-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
246 Su MJ, Aldawsari H, Amiji M. Pancreatic Cancer Cell Exosome-Mediated Macrophage Reprogramming and the Role of MicroRNAs 155 and 125b2 Transfection using Nanoparticle Delivery Systems. Sci Rep. 2016;6:30110. [PMID: 27443190 DOI: 10.1038/srep30110] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 16.0] [Reference Citation Analysis]
247 Liu Y, Du L. Role of pancreatic stellate cells and periostin in pancreatic cancer progression. Tumour Biol 2015;36:3171-7. [PMID: 25840689 DOI: 10.1007/s13277-015-3386-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
248 Farr N, Wang YN, D'Andrea S, Starr F, Partanen A, Gravelle KM, McCune JS, Risler LJ, Whang SG, Chang A, Hingorani SR, Lee D, Hwang JH. Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer. Int J Hyperthermia 2018;34:284-91. [PMID: 28715967 DOI: 10.1080/02656736.2017.1336675] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
249 Zhou H, Qian W, Uckun FM, Zhou Z, Wang L, Wang A, Mao H, Yang L. IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer. Proc SPIE Int Soc Opt Eng 2016;9836:98361O. [PMID: 27313332 DOI: 10.1117/12.2224914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
250 Sandhu V, Bowitz Lothe IM, Labori KJ, Skrede ML, Hamfjord J, Dalsgaard AM, Buanes T, Dube G, Kale MM, Sawant S, Kulkarni-Kale U, Børresen-Dale AL, Lingjærde OC, Kure EH. Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma. Mol Oncol 2016;10:303-16. [PMID: 26590090 DOI: 10.1016/j.molonc.2015.10.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
251 Bhardwaj A, Srivastava SK, Singh S, Tyagi N, Arora S, Carter JE, Khushman M, Singh AP. MYB Promotes Desmoplasia in Pancreatic Cancer through Direct Transcriptional Up-regulation and Cooperative Action of Sonic Hedgehog and Adrenomedullin. J Biol Chem 2016;291:16263-70. [PMID: 27246849 DOI: 10.1074/jbc.M116.732651] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
252 Birgin E, Hablawetz P, Téoule P, Rückert F, Wilhelm TJ. Chronic pancreatitis and resectable synchronous pancreatic carcinoma: A survival analysis. Pancreatology 2018;18:394-8. [PMID: 29716797 DOI: 10.1016/j.pan.2018.04.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
253 Liu Y, Li F, Gao F, Xing L, Qin P, Liang X, Zhang J, Qiao X, Lin L, Zhao Q, Du L. Periostin promotes tumor angiogenesis in pancreatic cancer via Erk/VEGF signaling. Oncotarget 2016;7:40148-59. [PMID: 27223086 DOI: 10.18632/oncotarget.9512] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
254 Shi S, Liang C, Xu J, Meng Q, Hua J, Yang X, Ni Q, Yu X. The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. Annals of Surgery 2020;271:559-65. [DOI: 10.1097/sla.0000000000002998] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
255 Fan Y, Sun Q, Li X, Feng J, Ao Z, Li X, Wang J. Substrate Stiffness Modulates the Growth, Phenotype, and Chemoresistance of Ovarian Cancer Cells. Front Cell Dev Biol 2021;9:718834. [PMID: 34504843 DOI: 10.3389/fcell.2021.718834] [Reference Citation Analysis]
256 Kim SJ, Chang S, Lee Y, Kim NY, Hwang Y, Min HJ, Yoo KS, Park EH, Kim S, Chung YH, Park YW, Koh SS. A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis. Biochem Biophys Res Commun 2014;454:144-50. [PMID: 25450371 DOI: 10.1016/j.bbrc.2014.10.056] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
257 Noel P, Hussein S, Ng S, Antal CE, Lin W, Rodela E, Delgado P, Naveed S, Downes M, Lin Y, Evans RM, Von Hoff DD, Han H. Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts. Oncogenesis 2020;9:100. [PMID: 33168807 DOI: 10.1038/s41389-020-00285-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
258 Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 25.0] [Reference Citation Analysis]
259 Prieto-García E, Díaz-García CV, Agudo-López A, Pardo-Marqués V, García-Consuegra I, Asensio-Peña S, Alonso-Riaño M, Pérez C, Gómez C, Adeva J, Paz-Ares L, López-Martín JA, Agulló-Ortuño MT. Tumor-Stromal Interactions in a Co-Culture Model of Human Pancreatic Adenocarcinoma Cells and Fibroblasts and Their Connection with Tumor Spread. Biomedicines 2021;9:364. [PMID: 33807441 DOI: 10.3390/biomedicines9040364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
260 Fuentes NR, Phan J, Huang Y, Lin D, Taniguchi CM. Resolving the HIF paradox in pancreatic cancer. Cancer Lett. 2020;489:50-55. [PMID: 32512024 DOI: 10.1016/j.canlet.2020.05.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
261 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 10.7] [Reference Citation Analysis]
262 Amrutkar M, Gladhaug IP. Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017;9. [PMID: 29144412 DOI: 10.3390/cancers9110157] [Cited by in Crossref: 142] [Cited by in F6Publishing: 140] [Article Influence: 35.5] [Reference Citation Analysis]
263 Zhao R, Han X, Li Y, Wang H, Ji T, Zhao Y, Nie G. Photothermal Effect Enhanced Cascade-Targeting Strategy for Improved Pancreatic Cancer Therapy by Gold Nanoshell@Mesoporous Silica Nanorod. ACS Nano 2017;11:8103-13. [PMID: 28738680 DOI: 10.1021/acsnano.7b02918] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 21.8] [Reference Citation Analysis]
264 Tomita Y, Azuma K, Nonaka Y, Kamada Y, Tomoeda M, Kishida M, Tanemura M, Miyoshi E. Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma. Pancreas. 2014;43:1032-1041. [PMID: 24991971 DOI: 10.1097/mpa.0000000000000159] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
265 Nissan N. Modifications of pancreatic diffusion MRI by tissue characteristics: what are we weighting for? NMR in Biomedicine 2017;30:e3728. [DOI: 10.1002/nbm.3728] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
266 Ding SM, Lu AL, Zhang W, Zhou L, Xie HY, Zheng SS, Li QY. The role of cancer-associated fibroblast MRC-5 in pancreatic cancer. J Cancer 2018;9:614-28. [PMID: 29483967 DOI: 10.7150/jca.19614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
267 Song H, Song J, Kim YJ, Jeong HH, Min HJ, Koh SS. DCPP1 is the mouse ortholog of human PAUF that possesses functional analogy in pancreatic cancer. Biochem Biophys Res Commun 2017;493:1498-503. [PMID: 28988106 DOI: 10.1016/j.bbrc.2017.10.015] [Reference Citation Analysis]
268 Hamada S, Masamune A, Shimosegawa T. Alteration of pancreatic cancer cell functions by tumor-stromal cell interaction. Front Physiol. 2013;4:318. [PMID: 24198790 DOI: 10.3389/fphys.2013.00318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
269 Chen Z, Huang J, Li M, Zhang L, Wan D, Lin S. High expression of MMP28 indicates unfavorable prognosis in pancreatic cancer. Medicine (Baltimore) 2021;100:e25320. [PMID: 33761734 DOI: 10.1097/MD.0000000000025320] [Reference Citation Analysis]
270 Park E, Yoo JE, Hwang HK, Kang CM, Lee CK, Kim MH, Bang S, Park YN. Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2021. [PMID: 34318617 DOI: 10.1002/jhbp.1025] [Reference Citation Analysis]
271 Guzzetta AA, Pisanic Ii TR, Sharma P, Yi JM, Stark A, Wang TH, Ahuja N. The promise of methylation on beads for cancer detection and treatment. Expert Rev Mol Diagn 2014;14:845-52. [PMID: 25136840 DOI: 10.1586/14737159.2014.943665] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
272 Papapanagiotou A, Sgourakis G, Karkoulias K, Raptis D, Parkin E, Brotzakis P, Panchal S, Papavassiliou AG. Osteonectin as a screening marker for pancreatic cancer: A prospective study. J Int Med Res. 2018;46:2769-2779. [PMID: 29756486 DOI: 10.1177/0300060518772413] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
273 Liu L, Kshirsagar P, Christiansen J, Gautam SK, Aithal A, Gulati M, Kumar S, Solheim JC, Batra SK, Jain M, Wannemuehler MJ, Narasimhan B. Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β. J Biomed Mater Res A 2021;109:893-902. [PMID: 32776461 DOI: 10.1002/jbm.a.37080] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
274 Tian L, Chang A, Melancon MP. Exploring gold nanoparticle interactions with proteins and the tumor microenvironment in biological systems. Transl Cancer Res 2017;6:S309-12. [PMID: 28690978 DOI: 10.21037/tcr.2017.03.53] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
275 Yuan W, Yang D, Su Q, Zhu X, Cao T, Sun Y, Dai Y, Feng W, Li F. Intraperitoneal Administration of Biointerface-Camouflaged Upconversion Nanoparticles for Contrast Enhanced Imaging of Pancreatic Cancer. Adv Funct Mater 2016;26:8631-42. [DOI: 10.1002/adfm.201603907] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
276 Zhang Q, Lou Y, Zhang J, Fu Q, Wei T, Sun X, Chen Q, Yang J, Bai X, Liang T. Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. Mol Cancer 2017;16:119. [PMID: 28705232 DOI: 10.1186/s12943-017-0689-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
277 Meng H, Zhao Y, Dong J, Xue M, Lin YS, Ji Z, Mai WX, Zhang H, Chang CH, Brinker CJ, Zink JI, Nel AE. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano 2013;7:10048-65. [PMID: 24143858 DOI: 10.1021/nn404083m] [Cited by in Crossref: 110] [Cited by in F6Publishing: 103] [Article Influence: 13.8] [Reference Citation Analysis]
278 Peng YP, Zhang JJ, Liang WB, Tu M, Lu ZP, Wei JS, Jiang KR, Gao WT, Wu JL, Xu ZK, Miao Y, Zhu Y. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. BMC Cancer. 2014;14:738. [PMID: 25274283 DOI: 10.1186/1471-2407-14-738] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
279 Qiu YA, Xiong J, Yu T. Role of G Protein-Coupled Estrogen Receptor in Digestive System Carcinomas: A Minireview. Onco Targets Ther 2021;14:2611-22. [PMID: 33888991 DOI: 10.2147/OTT.S291896] [Reference Citation Analysis]
280 Li S, Zhang W, Xing R, Yuan C, Xue H, Yan X. Supramolecular Nanofibrils Formed by Coassembly of Clinically Approved Drugs for Tumor Photothermal Immunotherapy. Adv Mater 2021;33:e2100595. [PMID: 33876464 DOI: 10.1002/adma.202100595] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
281 Maharjan S, Cecen B, Zhang YS. 3D Immunocompetent Organ-on-a-Chip Models. Small Methods 2020;4:2000235. [PMID: 33072861 DOI: 10.1002/smtd.202000235] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
282 Ruess DA, Görgülü K, Wörmann SM, Algül H. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs Aging 2017;34:331-57. [PMID: 28349415 DOI: 10.1007/s40266-017-0453-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
283 Hu D, Ansari D, Zhou Q, Sasor A, Said Hilmersson K, Andersson R. Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer. Scandinavian Journal of Gastroenterology 2019;54:246-51. [DOI: 10.1080/00365521.2019.1574360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
284 Barrett AS, Maller O, Pickup MW, Weaver VM, Hansen KC. Compartment resolved proteomics reveals a dynamic matrisome in a biomechanically driven model of pancreatic ductal adenocarcinoma. Journal of Immunology and Regenerative Medicine 2018;1:67-75. [DOI: 10.1016/j.regen.2018.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
285 Neuzillet C, de Gramont A, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget 2014;5:78-94. [PMID: 24393789 DOI: 10.18632/oncotarget.1569] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 11.4] [Reference Citation Analysis]
286 Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, Capretti G, Mineri R, Todoric J, Zerbi A. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut. 2016;65:1710-1720. [PMID: 26156960 DOI: 10.1136/gutjnl-2015-309193] [Cited by in Crossref: 99] [Cited by in F6Publishing: 99] [Article Influence: 16.5] [Reference Citation Analysis]
287 Afelik S, Pool B, Schmerr M, Penton C, Jensen J. Wnt7b is required for epithelial progenitor growth and operates during epithelial-to-mesenchymal signaling in pancreatic development. Developmental Biology 2015;399:204-17. [DOI: 10.1016/j.ydbio.2014.12.031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
288 Sclafani F, Iyer R, Cunningham D, Starling N. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. Crit Rev Oncol Hematol 2015;95:318-36. [PMID: 25921418 DOI: 10.1016/j.critrevonc.2015.03.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
289 Chronopoulos A, Robinson B, Sarper M, Cortes E, Auernheimer V, Lachowski D, Attwood S, García R, Ghassemi S, Fabry B, Del Río Hernández A. ATRA mechanically reprograms pancreatic stellate cells to suppress matrix remodelling and inhibit cancer cell invasion. Nat Commun 2016;7:12630. [PMID: 27600527 DOI: 10.1038/ncomms12630] [Cited by in Crossref: 121] [Cited by in F6Publishing: 118] [Article Influence: 24.2] [Reference Citation Analysis]
290 Neesse A, Algül H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64:1476-1484. [PMID: 25994217 DOI: 10.1136/gutjnl-2015-309304] [Cited by in Crossref: 281] [Cited by in F6Publishing: 269] [Article Influence: 46.8] [Reference Citation Analysis]
291 Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012;9:435-444. [PMID: 22733351 DOI: 10.1038/nrgastro.2012.119] [Cited by in Crossref: 139] [Cited by in F6Publishing: 131] [Article Influence: 15.4] [Reference Citation Analysis]
292 Mahajan UM, Langhoff E, Goni E, Costello E, Greenhalf W, Halloran C, Ormanns S, Kruger S, Boeck S, Ribback S, Beyer G, Dombroswki F, Weiss F, Neoptolemos JP, Werner J, D’haese JG, Bazhin A, Peterhansl J, Pichlmeier S, Büchler MW, Kleeff J, Ganeh P, Sendler M, Palmer DH, Kohlmann T, Rad R, Regel I, Lerch MM, Mayerle J. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology 2018;155:1625-1639.e2. [DOI: 10.1053/j.gastro.2018.08.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 23.0] [Reference Citation Analysis]
293 Ren B, Cui M, Yang G, Wang H, Feng M, You L, Zhao Y. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018;17:108. [PMID: 30060755 DOI: 10.1186/s12943-018-0858-1] [Cited by in Crossref: 101] [Cited by in F6Publishing: 112] [Article Influence: 33.7] [Reference Citation Analysis]
294 Hausmann S, Kong B, Michalski C, Erkan M, Friess H. The role of inflammation in pancreatic cancer. Adv Exp Med Biol. 2014;816:129-151. [PMID: 24818722 DOI: 10.1007/978-3-0348-0837-8_6] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 7.4] [Reference Citation Analysis]
295 Robinson BK, Cortes E, Rice AJ, Sarper M, Del Río Hernández A. Quantitative analysis of 3D extracellular matrix remodelling by pancreatic stellate cells. Biol Open 2016;5:875-82. [PMID: 27170254 DOI: 10.1242/bio.017632] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
296 Kristi N, Gafur A, Kong L, Ma X, Ye Z, Wang G. Atomic Force Microscopy in Mechanoimmunology Analysis: A New Perspective for Cancer Immunotherapy. Biotechnol J 2020;15:e1900559. [PMID: 32240578 DOI: 10.1002/biot.201900559] [Reference Citation Analysis]
297 Neuzillet C, Couvelard A, Tijeras-Raballand A, de Mestier L, de Gramont A, Bédossa P, Paradis V, Sauvanet A, Bachet JB, Ruszniewski P. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Histopathology. 2015;67:664-676. [PMID: 25809563 DOI: 10.1111/his.12691] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
298 Zhou Q, Bauden M, Andersson R, Hu D, Marko-Varga G, Xu J, Sasor A, Dai H, Pawłowski K, Said Hilmersson K, Chen X, Ansari D. YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling. J Transl Med 2020;18:77. [PMID: 32054505 DOI: 10.1186/s12967-020-02254-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 15.0] [Reference Citation Analysis]
299 Drifka CR, Loeffler AG, Mathewson K, Keikhosravi A, Eickhoff JC, Liu Y, Weber SM, Kao WJ, Eliceiri KW. Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection. Oncotarget 2016;7:76197-213. [PMID: 27776346 DOI: 10.18632/oncotarget.12772] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 27.7] [Reference Citation Analysis]
300 Kanat O, Ertas H. Shattering the castle walls: Anti-stromal therapy for pancreatic cancer. World J Gastrointest Oncol 2018; 10(8): 202-210 [PMID: 30147846 DOI: 10.4251/wjgo.v10.i8.202] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
301 Torres C, Perales S, Alejandre MJ, Iglesias J, Palomino RJ, Martin M, Caba O, Prados JC, Aránega A, Delgado JR, Irigoyen A, Ortuño FM, Rojas I, Linares A. Serum cytokine profile in patients with pancreatic cancer. Pancreas 2014;43:1042-9. [PMID: 24979617 DOI: 10.1097/MPA.0000000000000155] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
302 Ziani L, Chouaib S, Thiery J. Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts. Front Immunol 2018;9:414. [PMID: 29545811 DOI: 10.3389/fimmu.2018.00414] [Cited by in Crossref: 123] [Cited by in F6Publishing: 119] [Article Influence: 41.0] [Reference Citation Analysis]
303 Erkan M, Hausmann S, Michalski CW, Schlitter AM, Fingerle AA, Dobritz M, Friess H, Kleeff J. How fibrosis influences imaging and surgical decisions in pancreatic cancer. Front Physiol. 2012;3:389. [PMID: 23060813 DOI: 10.3389/fphys.2012.00389] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
304 Ware MJ, Curtis LT, Wu M, Ho JC, Corr SJ, Curley SA, Godin B, Frieboes HB. Pancreatic adenocarcinoma response to chemotherapy enhanced with non-invasive radio frequency evaluated via an integrated experimental/computational approach. Sci Rep 2017;7:3437. [PMID: 28611425 DOI: 10.1038/s41598-017-03040-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
305 Parente P, Parcesepe P, Covelli C, Olivieri N, Remo A, Pancione M, Latiano TP, Graziano P, Maiello E, Giordano G. Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches. Gastroenterol Res Pract. 2018;2018:7530619. [PMID: 30662458 DOI: 10.1155/2018/7530619] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
306 Poh AR, Ernst M. Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges. Cancers (Basel) 2021;13:2860. [PMID: 34201127 DOI: 10.3390/cancers13122860] [Reference Citation Analysis]
307 Ahmad IM, Dafferner AJ, O'Connell KA, Mehla K, Britigan BE, Hollingsworth MA, Abdalla MY. Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:2264. [PMID: 34066839 DOI: 10.3390/cancers13092264] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
308 Chen X, Jia F, Li Y, Deng Y, Huang Y, Liu W, Jin Q, Ji J. Nitric oxide-induced stromal depletion for improved nanoparticle penetration in pancreatic cancer treatment. Biomaterials 2020;246:119999. [PMID: 32247201 DOI: 10.1016/j.biomaterials.2020.119999] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
309 Kleger A, Perkhofer L, Seufferlein T. Smarter drugs emerging in pancreatic cancer therapy. Ann Oncol. 2014;25:1260-1270. [PMID: 24631947 DOI: 10.1093/annonc/mdu013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 8.0] [Reference Citation Analysis]
310 Liu Z, Zhang L, Tian Z, Kong C, Liu C, Liu H, Yuan F, Kong W, Qian F. Paclitaxel and Itraconazole Co‐Encapsulated Micelle Prolongs the Survival of Spontaneous LSL‐Kras G12D/+ , LSL‐Trp53 R172H/+ , Pdx‐1‐Cre Genetically Engineered Mouse Model of Pancreatic Cancer. Adv Therap 2019;2:1900032. [DOI: 10.1002/adtp.201900032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
311 Barhli A, Cros J, Bartholin L, Neuzillet C. Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future. Dig Liver Dis 2018;50:979-90. [PMID: 30205952 DOI: 10.1016/j.dld.2018.08.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
312 Manuel ER, Chen J, D'Apuzzo M, Lampa MG, Kaltcheva TI, Thompson CB, Ludwig T, Chung V, Diamond DJ. Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. Cancer Immunol Res 2015;3:1096-107. [PMID: 26134178 DOI: 10.1158/2326-6066.CIR-14-0214] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
313 Daman Z, Faghihi H, Montazeri H. Salinomycin nanoparticles interfere with tumor cell growth and the tumor microenvironment in an orthotopic model of pancreatic cancer. Drug Dev Ind Pharm 2018;44:1434-42. [PMID: 29619850 DOI: 10.1080/03639045.2018.1459674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
314 Sun Y, Cao J, Wang X, Zhang C, Luo J, Zeng Y, Zhang C, Li Q, Zhang Y, Xu W, Zhang T, Huang P. Hypoxia-Adapted Sono-chemodynamic Treatment of Orthotopic Pancreatic Carcinoma Using Copper Metal-Organic Frameworks Loaded with an Ultrasound-Induced Free Radical Initiator. ACS Appl Mater Interfaces 2021;13:38114-26. [PMID: 34357760 DOI: 10.1021/acsami.1c11017] [Reference Citation Analysis]
315 Arlauckas SP, Browning EA, Poptani H, Delikatny EJ. Imaging of cancer lipid metabolism in response to therapy. NMR in Biomedicine 2018;32. [DOI: 10.1002/nbm.4070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
316 Han S, Delitto D, Zhang D, Sorenson HL, Sarosi GA, Thomas RM, Behrns KE, Wallet SM, Trevino JG, Hughes SJ. Primary outgrowth cultures are a reliable source of human pancreatic stellate cells. Lab Invest 2015;95:1331-40. [PMID: 26322418 DOI: 10.1038/labinvest.2015.117] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
317 Mahmud M, Piwoni A, Filipczak N, Janicka M, Gubernator J. Long-Circulating Curcumin-Loaded Liposome Formulations with High Incorporation Efficiency, Stability and Anticancer Activity towards Pancreatic Adenocarcinoma Cell Lines In Vitro. PLoS One 2016;11:e0167787. [PMID: 27936114 DOI: 10.1371/journal.pone.0167787] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
318 Sinn M, Denkert C, Striefler JK, Pelzer U, Stieler JM, Bahra M, Lohneis P, Dörken B, Oettle H, Riess H. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br J Cancer. 2014;111:1917-1923. [PMID: 25314063 DOI: 10.1038/bjc.2014.495] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 10.6] [Reference Citation Analysis]
319 Rahnamay Farnood P, Danesh Pazhooh R, Asemi Z, Yousefi B. DNA damage response and repair in pancreatic cancer development and therapy. DNA Repair (Amst) 2021;103:103116. [PMID: 33882393 DOI: 10.1016/j.dnarep.2021.103116] [Reference Citation Analysis]
320 Carpenter E, Nelson S, Bednar F, Cho C, Nathan H, Sahai V, di Magliano MP, Frankel TL. Immunotherapy for pancreatic ductal adenocarcinoma. J Surg Oncol 2021;123:751-9. [PMID: 33595893 DOI: 10.1002/jso.26312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
321 Kramer-Marek G, Gore J, Korc M. Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions. Cancer Lett 2013;341:132-8. [PMID: 23941833 DOI: 10.1016/j.canlet.2013.08.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
322 Neel NF, Stratford JK, Shinde V, Ecsedy JA, Martin TD, Der CJ, Yeh JJ. Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation. Mol Cancer Ther 2014;13:122-33. [PMID: 24222664 DOI: 10.1158/1535-7163.MCT-12-1232] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
323 Chen X, An Y, Zhang Y, Xu D, Chen T, Yang Y, Chen W, Wu D, Zhang X. CCL26 is upregulated by nab-paclitaxel in pancreatic cancer-associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K/AKT/mTOR pathway. Acta Biochim Biophys Sin (Shanghai) 2021;53:612-9. [PMID: 33764366 DOI: 10.1093/abbs/gmab032] [Reference Citation Analysis]
324 Bokas A, Papakotoulas P, Sarantis P, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas. Cancers (Basel) 2020;12:E432. [PMID: 32069809 DOI: 10.3390/cancers12020432] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
325 Hussain SS, Patel D, Ghosh R, Kumar AP. Extracting the Benefit of Nexrutine® for Cancer Prevention. Curr Pharmacol Rep 2015;1:365-72. [DOI: 10.1007/s40495-015-0029-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
326 Caba O, Prados J, Ortiz R, Jiménez-Luna C, Melguizo C, Alvarez PJ, Delgado JR, Irigoyen A, Rojas I, Pérez-Florido J, Torres C, Perales S, Linares A, Aránega A. Transcriptional profiling of peripheral blood in pancreatic adenocarcinoma patients identifies diagnostic biomarkers. Dig Dis Sci 2014;59:2714-20. [PMID: 25069573 DOI: 10.1007/s10620-014-3291-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
327 Song Y, Sun X, Duan F, He C, Wu J, Huang X, Xing K, Sun S, Wang R, Xie F, Mao Y, Wang J, Li S. SYPL1 Inhibits Apoptosis in Pancreatic Ductal Adenocarcinoma via Suppression of ROS-Induced ERK Activation. Front Oncol 2020;10:1482. [PMID: 33042794 DOI: 10.3389/fonc.2020.01482] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
328 Rice AJ, Cortes E, Lachowski D, Cheung BCH, Karim SA, Morton JP, Del Río Hernández A. Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis 2017;6:e352. [PMID: 28671675 DOI: 10.1038/oncsis.2017.54] [Cited by in Crossref: 162] [Cited by in F6Publishing: 168] [Article Influence: 40.5] [Reference Citation Analysis]
329 Yan M, Shen M, Xu L, Huang J, He G, An M, Li X, Gao Z, Meng X. Inactivation of Pancreatic Stellate Cells by Exendin-4 Inhibits the Migration and Invasion of Pancreatic Cancer Cells. Onco Targets Ther 2020;13:9455-63. [PMID: 33061431 DOI: 10.2147/OTT.S259853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Yeo D, Phillips P, Baldwin GS, He H, Nikfarjam M. Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer. Int J Cancer. 2017;140:2101-2111. [PMID: 28109008 DOI: 10.1002/ijc.30615] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
331 Conrad C, Benzel J, Dorzweiler K, Cook L, Schlomann U, Zarbock A, Slater EP, Nimsky C, Bartsch JW. ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance. Clin Sci (Lond) 2019;133:83-99. [PMID: 30635388 DOI: 10.1042/CS20180906] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
332 Dosch AR, Dai X, Reyzer ML, Mehra S, Srinivasan S, Willobee BA, Kwon D, Kashikar N, Caprioli R, Merchant NB, Nagathihalli NS. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. Mol Cancer Res 2020;18:623-31. [PMID: 31949002 DOI: 10.1158/1541-7786.MCR-19-0741] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 13.0] [Reference Citation Analysis]
333 Yu Y, Yang G, Huang H, Fu Z, Cao Z, Zheng L, You L, Zhang T. Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine. J Exp Clin Cancer Res 2021;40:8. [PMID: 33402215 DOI: 10.1186/s13046-020-01787-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
334 Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia AM, Höfling S, Parsons M, Costa P, Soper R, Bossard M, Hagemann T, Roshani R, Sewald N, Ketchem RR, Moss ML, Rasmussen FH, Miller MA, Lauffenburger DA, Tuveson DA, Nimsky C, Bartsch JW. ADAM8 as a drug target in pancreatic cancer. Nat Commun 2015;6:6175. [PMID: 25629724 DOI: 10.1038/ncomms7175] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 9.7] [Reference Citation Analysis]
335 Meng H, Nel AE. Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer. Adv Drug Deliv Rev 2018;130:50-7. [PMID: 29958925 DOI: 10.1016/j.addr.2018.06.014] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
336 Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther. 2015;155:80-104. [PMID: 26299994 DOI: 10.1016/j.pharmthera.2015.08.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 9.7] [Reference Citation Analysis]
337 Yoshida GJ, Azuma A, Miura Y, Orimo A. Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies. Int J Mol Sci 2019;20:E2256. [PMID: 31067787 DOI: 10.3390/ijms20092256] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 27.0] [Reference Citation Analysis]
338 Wu ST, Fowler AJ, Garmon CB, Fessler AB, Ogle JD, Grover KR, Allen BC, Williams CD, Zhou R, Yazdanifar M, Ogle CA, Mukherjee P. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles. BMC Cancer 2018;18:457. [PMID: 29685122 DOI: 10.1186/s12885-018-4393-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
339 Tanaka HY, Kano MR. Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment. Cancer Sci 2018;109:2085-92. [PMID: 29737600 DOI: 10.1111/cas.13630] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
340 Nones K, Waddell N, Song S, Patch AM, Miller D, Johns A, Wu J, Kassahn KS, Wood D, Bailey P. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer. 2014;135:1110-1118. [PMID: 24500968 DOI: 10.1002/ijc.28765] [Cited by in Crossref: 129] [Cited by in F6Publishing: 111] [Article Influence: 18.4] [Reference Citation Analysis]